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Despite significant advances in the efficacy of immunotherapies that target 
increasingly specific inflammatory elements critical to the development of the 
disease, there remains a significant therapeutic shortfall for sufferers of Multiple 
Sclerosis (MS).  The pathophysiological disconnect between inflammation and the 
neurodegeneration that ultimately underlines disability is well described and 
continues to limit the success of increasingly potent immunosuppression.   
 
Neuroprotection, immunomodulation and cell replacement, all demonstrable 
properties of adult multipotent mesenchymal stem cells (MSCs) offer further 
therapeutic potential that may help to address both the inflammatory disease 
component and the neuronal loss that underscores disability.  Much work has been 
done over the last decade and more to elucidate these properties with the 
accumulation of a critical body of evidence enabling translation to clinical trials 
including in Bristol.   
 
Animal models of inflammatory neurological pathology have yielded many clues to 
the mode of activity of MSCs.  Detailed knowledge of their pathophysiological role 
in man however is lacking.    
 
This thesis was principally directed towards supporting and refining the imminent 
translational study.  The aim of this work was twofold; to identify stem cell 
populations with proven advantageous properties in the bloodstream and in the 
brains of individuals with MS and interrogation of Neurophysiological outcome 
measures as a surrogate for disability measures. 
 
Stem cells of the bone marrow niche were identified in patients undergoing clinical 
relapse, as well as in those taking commonly prescribed disease modifying 
therapies.  Whilst MSCs were readily identified in bone marrow samples, they were 
not detectable in peripheral blood at current technological thresholds.  Cells 
expressing markers commonly expressed by MSCs were also identified in post-
mortem brain tissue from individuals with active MS, suggesting possible central 
nervous system infiltration.  Finally evoked potential-based composite scores were 
demonstrated to correlate with clinical disability scoring methods both in cross-
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The earliest recordings of the disease process that has come to be called Multiple 
Sclerosis may be found in references to the spontaneous resolution of sight in 
young females in biblical teachings or Norse mythology.  Examples of MS were 
undoubtedly contained in case series of paraplegia and limb palsy produced in early 
efforts at systematic descriptions of what has become known as Neurological 
disease.  The first depiction of MS appears in 1838 in Robert Carswell’s famous book 
Pathological anatomy: illustrations of the elementary forms of disease.  More 
detailed and systematic descriptions of the disease were produced by Jean-Martin 
Charcot at the latter end of the 19th century.  The initial terminology of sclerose en 
plaque disseminees or disseminated sclerosis was only replaced by the modern day 
multiple sclerosis in the mid-20th century when consensus was reached primarily 
through the organisation of patient support groups and then finally with publication 
of the first edition of McAlpine’s Multiple Sclerosis.  As the 19th century progressed 
progressively more light was shone on the processes underlying the disease with 
the advent at the turn of the century of the first effective disease-modifying 
therapeutic agents.  Much however remains enigmatic and the therapeutic needs 




Multiple sclerosis is the commonest cause of non-traumatic disability in young 
adults (Sadovnick and Ebers, 1993) with a UK prevalence of between 103-186 per 
100,000 (Pugliatti et al., 2006).  Worldwide, estimates put the number of affected 
individuals at more than 2.5 million (Compston and Coles, 2002).  Costs associated 
with the disease are significant and proportional to the level of disability; in 2006 
UK costs were estimated at £12,000 for those with an EDSS <4 and £60,000 with 
EDSS of 7 or more (Kobelt et al., 2006).  Overall costs were not calculated in this 
study due to insufficient prevalence data but were estimated to be 40% higher than 
the £1.9 billion calculated by a Stockholm School of Economics working paper in 
2000.  A significant proportion of associated costs are due to increasingly expensive 
disease-modifying therapies. 
 
Multiple sclerosis, as with other autoimmune disease, is more common in women.  
The generally agreed ratio is F:M - 2:1 though the proportion of females has varied 
from a maximum of 71% in some US and New Zealand case series (Miller et al., 
1992; Visscher et al., 1984) to 51% in several Israeli series (Leibowitz et al., 1973).  
Peak age of onset is roughly 30.  Though a significant proportion of patients 
experience onset of the disease before they are 20, it is rare in children.  In this 
group, as with the over 50’s, alternative diagnoses should be explored thoroughly. 
The hallmark of multiple sclerosis is the presence of demyelinated plaques in the 
CNS with dissemination in time and space.  Clinical, biological, electrophysiological 
and radiological surrogates of the process are utilised in the diagnosis of the 
disease.  Diagnostic criteria have been developed to standardise epidemiological 
study, therapeutic trials and, with the advent of potentially harmful DMDs, clinical 
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practice.  The first of these were developed by Poser and colleagues (Poser et al., 
1983) generating clinically and laboratory-supported definite and probable MS.  
The difficulties posed by primary progressive disease were first addressed by 
Thompson and colleagues (Thompson et al., 2000) who distinguished the entity by 
clinical progression for at least one year with 3 levels of diagnostic certainty, 
established using clinical parameters, MRI criteria, the presence of intra-thecal 
oligocloncal band synthesis and visual evoked potentials.  Further evolution of 
diagnostic criteria has taken place over the last 15 years to enable earlier confident 
diagnosis (particularly relevant in the light of increasing therapeutic options) and to 
allow adaptation to accumulating evidence of the predictive value of laboratory 
tests.  In 2001 an International Panel produced the ‘McDonald criteria’ (McDonald 
et al., 2001) unifying diagnostic criteria for both relapsing and progressive from 
onset disease. 
 
The clinical course of Multiple Sclerosis is well documented.  Current consensus 
classifies disease into one of four categories; primary progressive, relapsing-
remitting, secondary progressive and relapsing progressive disease (Lublin and 
Reingold, 1996).  80-85% of patients experience acute, rapid onset symptoms, a 
‘relapse’, as the first clinical sign of the disease (Confavreux et al., 1980; Poser et 
al., 1982) (although often, a prior episode that was either trivialised or 
misdiagnosed, is apparent on taking a detailed neurological history).  The first 
episode was previously referred to as a clinically isolated syndrome; not all cases 
will show disease recurrence or progression to establish a diagnosis of MS.  
Evidence of subclinical disease activity on neuroimaging increases the likelihood of 
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further clinical relapses (Fisniku et al., 2008).  The average rate of relapse is difficult 
to establish definitively due to potential mimics (including transient neuronal 
dysfunction due to environmental challenges to saltatory conduction in the CNS – 
so-called ‘pseudo-relapses’) and lack of a ‘gold standard’ confirmatory clinical test.  
Retrospective reporting estimates relapse rates of generally <0.5 per year 
(McALPINE and COMPSTON, 1952; Myhr et al., 2001) and prospective assessments 
at slightly higher rates of 0.5-1.0 (Confavreux et al., 1980).  Rarely does average 
relapse frequency exceed 1.5 per year (Compston and Coles, 2008).  One of the 
most difficult aspects to reconcile for the patient with MS is the unpredictable 
nature of relapses which can strike at any time.  Recovery is often incomplete 
following each relapse and with time there is slow accumulation of disability.  In 
time, 65% of patients will enter a progressive phase of the disease – secondary 
progressive MS; whilst in 15-20% the disease is progressive from onset – primary 
progressive disease (Confavreux et al., 1980; Poser et al., 1982).  Entry into the 
progressive phenotype of the disease occurs at roughly the same age (40), 
regardless of the presence of antecedent relapses (Confavreux and Vukusic, 2006a).  
At present, there are no reliable biomarkers that can predict both if and when 
patients with relapsing disease will enter the progressive phases – this is one of 
many areas of current research priority.  Analysis of the death of participants in 
longitudinal studies, whilst relatively infrequent (e.g. 16/1099 patients in the 
Ontario cohort) demonstrate a median time to death from onset of MS of 30 years.  
This figure is supported by data from a Danish study looking specifically at death 
rather than disease progression in which 4254/9881 participants had died 
(Brønnum-Hansen et al., 2004). 
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Aetiology of Multiple Sclerosis 
 
Epidemiological studies in MS have provided useful insights into the genetic and 
environmental contribution to disease manifestation.  Neither provides an 
explanation of the distribution of the disease in isolation.  Findings point to a 
multifactorial aetiology with disease occurrence in genetically at-risk individuals 
exposed to requisite environmental conditions.   
 
Evidence from epidemiological studies demonstrates two consistent findings; MS 
clusters in families (Robertson et al., 1996) and rates of MS vary widely across the 
globe (Simpson et al., 2011).  These and more detailed subgroup findings suggest 
both play a role in the causation of MS; migrant studies have been particularly 
informative in this context.  Evidence for the genetic component of MS comes from 
twin studies demonstrating concordance of 25% in monozygotic twins (up to 35% 
in female twins) (Willer et al., 2003).  This and evidence from analysis of twins, 
adoptees and migrants point to a polygenic model with a moderate effect allele 
(odds ratio ~3-4) and multiple smaller effect alleles (odds ratio <1.5) (Sawcer et al., 
2014).  Associations between MS and variation in the major histocompatibility 
complex genes encoding the human leucocyte antigen were first identified in the 
1970s (Naito et al., 1972).  Interrogation of the allelic association of biologically 
plausible/relevant complexes targeted genetic research within the field of MS over 
subsequent decades.  Early work focusing on HLA-A3 and B7 (Jersild et al., 1972) 
has been refined and has established the allelic association of the HLA molecules 
DR15 - with DRB1*1501 (the main risk allele for MS) and DRB5*0101, and DQ6 - 
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with DQA1*0102 and DQB2*0602.  Alongside this work, linkage of genes within the 
MHC complex and susceptibility to MS has been interrogated, and in some 
commentator’s eyes resolved, through studies analysing large numbers of affected 
families (Ebers et al., 1996; Sawcer et al., 1996).  Prior to the advent of whole 
genome association studies little progress was made in identifying risk alleles out 
with the MHC.  The largest genome-wide association study thus far has identified 
57 single nucleotide polymorphism (SNP) associations (Sawcer et al., 2011) with a 
further 2 added in subsequent studies (Lill et al., 2013; Patsopoulos et al., 2011).  
The identified SNPs are notable for a high proportion with an association with 
immune system function, particularly in the domain of T cell differentiation.  
Broadly speaking candidate genes fall into one of several different categories 
including; cytokines involved in immune cell interaction, chemokines, cell adhesion 
molecules, inflammatory mediators and growth factors. 
 
Evidence suggests that geographical variation is explained by a combination of 
genetic and environmental factors.  A latitudinal gradient with higher rates of MS 
being associated with increasing distance from the equator (Simpson et al., 2011) 
has been established.  Some of the inconsistencies in this somewhat simplified 
model can be explained by correction for genetic factors/risk alleles.  The most 
likely environmental factor explaining the regional variation is levels of UV light and 
vitamin D synthesis in native populations.  Analysis of migrant populations affords 
significant clues to the interplay between genetic and environmental factors.  
Populations in Australia migrated from Europe have gradients of frequency that do 
not follow genetic inheritance patterns but remain correlated with latitude 
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(Hammond et al., 1988).  Furthermore, the rates of MS in immigrant populations 
demonstrates that those that move before age 15 adopt the incidence of the 
location to which they move whereas if moving after 15 they retain the risks of the 
population from which they emigrated (Dean, 1967).  Some have attempted to 
correct for age and sex and found that the north-south gradient for age and sex-
adjusted prevalence diminishes and age-adjusted incidence disappears completely, 
suggesting that distribution may be an artefact of demographic differences 
(Zivadinov et al., 2003), though this is contended.   
 
Environmental triggers have been hypothesised for some time but systematic 
evidence is lacking.  Putative candidates have included both infective and non-
infective agents.  Work in Sweden (Lindberg et al., 1991) and the UK (Martyn et al., 
1993) suggested an increased relative risk of developing MS in the context of prior 
Epstein Barr Virus (EBV) infection.  Further evidence implicating EBV in the aetiology 
and development of MS comes from immunological studies demonstrating 
molecular mimicry by the virus of Myelin Basic Protein (MBP) epitopes (Lang et al., 
2002).  Other potential agents that have attracted significant attention include 
Human Herpes Virus 6 (HHV6) (Ablashi et al., 1998; Chapenko et al., 2003) and 
Chlamydia pneumonia (Sriram et al., 1999) though evidence is contradictory and 
candidature insecure.  Various non-infectious agents have been postulated to play 
a role in the development of MS including parity, exogenous hormones, trauma and 





Pathology of Multiple Sclerosis 
 
The pathological findings in MS are central to the disease and its description – 
indeed even its name.  The central underlying disease process is inflammation 
leading to the destruction of myelin sheaths and demyelination.  This is the 
essential lesion, occurring throughout the CNS with particular prevalence for 
periventricular white matter, the spinal cord and optic nerves.  The process is 
accompanied by astrocytosis and scar formation resulting in the visible plaques that 
give the condition its name. 
 
Pathological description of the disease began with the observations of Carswell in 
1838 of multiple discoloured and indurated lesions throughout the CNS (Carswell, 
1838).  Correlation with a clinical phenotype was lacking other than a description 
of simply ‘paralysis’.  The illustrations were based on 2 French cases in whom 
Carswell records ‘I could not ascertain that there was anything in the character of 
the paralysis or the history of the cases calculated to throw any light on the nature 
of the lesion found in the spinal cord’.  There is however little doubt that the lesions 
represented are the first identification of the pathology of MS.  Later in the 19th 
century, and still at a remarkably early stage, Eduard Rindfleisch made several 
observations of some of the core pathological features of the condition including 
loss of myelin, formation of scar tissue and the orientation of lesions around 
medium-sized blood vessels (Rindfleisch, 1863).  The first systematic pathological 
description was made by Charcot in 1868 (Charcot, 1868) and has been regularly 
expanded ever since. 
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Classical Multiple Sclerosis is only one of several different types of demyelinating 
diseases that affect the human nervous system.  There is evidence that this 
apparently clinically disparate group of conditions causing widely varying 
phenotypes do in fact share very similar pathogenetic mechanisms.  Cases in which 
various combinations coexist have occasionally been reported.  Furthermore the 
entire spectrum of human inflammatory disease can be reproduced in experimental 
models of inflammatory disease simply by using different methods of immuno-
stimulation (Lassmann, 1983).  These include;  
- acute or Marburg variant MS (Marburg, 1906) in which there are particularly 
destructive lesions spread throughout the central and peripheral nervous 
system 
- concentric sclerosis of Balo (Balo, 1928) in which unknown mechanisms 
cause alternating rims of myelin preservation and loss leading to the typical 
onion bulb lesions 
- neuromyelitis optica caused by antibodies to a transmembrane protein 
(aquaporin 4) found in high concentration in the spinal cord and optic nerve 
(Devic, 1894) 
- acute demyelinating encephalomyelitis and transverse myelitis; a 
monophasic condition often associated with prior vaccination or infection, 
with more extreme cases resulting in perivascular haemorrhage and brain 
oedema (acute haemorrhagic leukoencephalomyelitis) 
- acute (Guillain et al., 1916) and chronic (Albers and Kelly, 1989) forms of 
inflammatory demyelinating peripheral polyneuropathy in which there is 
demyelination of peripheral nerves and in severe cases axonopathy 
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In the classical plaque of multiple sclerosis axons are demyelinated but preserved 
in an astrocytic scar matrix.  Plaques are centred on medium sized vessels 
(Rindfleisch, 1863) with prevalence in periventricular white matter and the outer 
surface of the brain (Steiner, 1931) and in the spinal cord (Oppenheimer, 1978).  
Histological specimens can only ever provide snapshots of a dynamic disease 
process.  Lesions or plaques can be broadly classified as active, chronic active and 
inactive.   
 
In actively demyelinating lesions myelin degradation products are identified within 
infiltrating macrophages which are abundant (Brück et al., 1995; Gay et al., 1997).  
Chronic active lesions are characterised by a rim of activated microglia and active 
demyelination at the periphery of the lesion, surrounding a central area of 
completed demyelination.  In the later stages of disease, when there is progressive 
clinical deterioration, it is unclear whether microscopic areas of ongoing active 
inflammation represent an active disease process or a response to secondary 
Wallerian degeneration.  The progression of an active lesion to inactivity is not of 
course binary.  Studies have identified the persistence of macrophages with myelin 
degradation products for months in Wallerian degeneration (Lumsden, 1970), and 
the presence of free lipids on MR spectroscopic analysis for several months after 
lesion initiation (Davie et al., 1994).  In so-called destructive lesions, there is 
extensive additional tissue destruction affecting both astrocytes and axons – seen 




Areas of incomplete demyelination were first identified by Marburg in 1906 
(Marburg, 1906).  The term Markschattenherde, translated as shadow plaque, was 
introduced by Schlesinger 3 years later (Schlesinger, 1909).  These were some of 
the first pieces of evidence hinting at the capacity for repair of damaged myelin in 
MS – further studies later provided strong evidence that they represent completed 
remyelination of a previously demyelinated plaque (Lassmann, 1983).  Other types 
of lesion include the previously discussed Balo’s concentric plaque and so-termed 
preactive lesions – areas in which there is evidence of inflammation, limited 
breakdown of the blood-brain barrier and reduced myelin density (De Groot et al., 
2001; Gay et al., 1997). 
 
Relatively recent advances in our understanding of the pathogenesis of tissue injury 
in MS have revealed a degree of heterogeneity not previously appreciated.  In 2000, 
Luchinetti and colleagues demonstrated 4 distinct patterns of tissue damage in a 
biopsy and autopsy series of 84 patients with MS (Lucchinetti et al., 2000), 
distinguished by a combination of their cellular reaction, patterns of 
oligodendrocyte loss and the immunopathological picture.   
 
In the first, termed basic general pattern, there is a dominant class 1 MHC-restricted 
T-lymphocyte and macrophage infiltrate with activation of resident microglia.  
Macrophages produce a variety of oxidative and nitrative molecules (Witherick et 
al., 2010), cytotoxic cytokines (Cannella and Raine, 1995) and proteolytic and 
lipolytic enzymes (Cuzner et al., 1996) which further mediate tissue damage.  The 
macrophages and microglia form clusters that are closely associated with 
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demyelinating fibres and disintegrating axons, but are also dispersed throughout 
normal appearing white matter.  Class 1 MHC molecules are found on various glial 
cells including oligodendrocytes (Höftberger et al., 2004) with CD8+ T-cells in close 
association (Neumann et al., 2002) and with features suggestive of a cytotoxic 
interaction resulting in characteristic apoptosis.  Areas of tissue injury form 
confluent demyelinated lesions with axonal sparing.  New oligodendrocytes are 
recruited to the area of damage and remylelination is extensive and frequent.  In 
more advanced cases with a progressive phenotype, oligodendrocyte numbers 
dwindle and remyelination is infrequent (Prineas et al., 2001). 
 
In pattern II, there is antibody-mediated demyelination in addition to the 
mechanisms found in the basic general pattern of lesion.  Deposition of antibodies 
is accompanied by activation of the complement cascade and absence of 
complement inhibitory proteins (Storch et al., 1998).  Complement activation is only 
observed in the earliest stages of lesion formation.  The antibody-mediated 
demyelination is associated with greater numbers of B-cells than pattern I, and 
resulting plaques are more sharply demarcated.  Oligodendrocyte recruitment and 
evidence of extensive remyelination is prevalent in pattern II lesions which are 
effectively indicative of early chronic disease.  Neuromyelitis optica represents an 
archetypal example of antibody mediated demyelination. 
 
In pattern III there is augmentation of tissue destruction by hypoxic mechanisms 
thought to include oedema and inflammation of vessel walls and impairment of 
mitochondrial function by reactive oxygen and nitrogen species.  Lesions contain 
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fewer foamy macrophages and microglial activation is less marked.  Chemokine 
expression is more in keeping with an ischaemic lesion rather than the pattern seen 
in the more ‘classical’ MS patterns – I and II.  Balo’s concentric sclerosis is one of 
the more extreme examples of pattern III pathology.  Elsewhere, plaques are ill-
defined and there is characteristic preservation of myelin immediately surrounding 
the small vessels on which the lesions are centred (Aboul-Enein et al., 2003). 
 
In pattern IV there is augmentation of demyelination that is thought to be related 
to a genetically-determined heightened susceptibility.  Such lesions are seen in 
patients with functional deficits in ciliary neurotrophic factor and more aggressive 
clinical disease (Giess et al., 2002).  Candidate genes thought to alter outcomes in 
inflammatory demyelinating disease include apolipoprotein E (Fazekas et al., 2000), 
mitochondrial DNA (Mojon et al., 1999), spinocerebellar ataxia gene 2 (Chataway 
et al., 1999) and p53 (Wosik et al., 2003). 
 
Patterns of demyelination classified according to the above criteria are strikingly 
homogenous when looking at tissue samples from an individual with MS taken at a 
single time point (Lucchinetti et al., 2000).  Clear differences are seen between 
individuals however, suggesting that the pattern changes according to disease 
stage.  In the acute phases of the disease pattern III predominates with patterns I 
and II more commonly encountered in the early chronic phases of the disease.  The 
clinical manifestation of these patterns are most evident in Balo’s sclerosis and 
Devic’s disease in which pattern IV and pattern II respectively convey the degree 
and nature of tissue destruction. 
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Immunology of Multiple Sclerosis  
 
The establishment of the sclerotic plaque is the culmination of several processes 
including inflammation, demyelination, remyelination and gliosis.  The relationship 
between these disease processes and the neurodegeneration that is thought to be 
responsible for the accumulation of disability in the condition is yet to be fully 
reconciled and remains in some quarters a point of debate.  The most prevalent 
theories hypothesise that the index event is regulatory failure of migrating 
lymphocytes though it has been argued that immunological activation may be a 
response to an underlying neurodegenerative process (Stys et al., 2012), a theory 
not without merit.  Whilst the debate persists, it is undeniable that the 
inflammatory process is central to manifestation of the disease. 
 
The inflammatory model/doctrine states that disease begins with transition from 
physiological immune surveillance to excessive migration of auto-reactive 
lymphocytes across the blood-brain barrier and establishment of an immune 
response within the CNS parenchyma.  The disease was traditionally thought to be 
a T-cell dependent process with macrophage-driven demyelination due to aberrant 
targeting of a myelin-specific autoantigen.  Evidence for the central role of T cells 
includes the presence of Th (T helper) 1 cytokines, receptors and cells in the CSF, 
circulation and lesions of MS patients (Cannella and Raine, 1995; Merrill, 1992; 
Navikas and Link, 1996).  It was commonly held that disease progression was driven 
by CD4+ effector cells.  Failure of regulatory lymphocytes to induce apoptosis in 
these cells has been demonstrated to be due to both afferent (regulatory cells from 
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patients with MS fail to suppress effector cells in-vitro (Viglietta et al., 2004)) and 
efferent mechanisms (overexpression of β-arrestin 1, a promoter of CD4+ cell 
survival, prevents effective apoptosis in the effector cell population (Shi et al., 
2007)).  Further evidence for the central role of these cells comes from the fact that 
CD4+ T cells polarized to the Th1 phenotype are thought to play a central role in the 
animal model of MS, experimental autoimmune encephalomyelitis (Khoruts et al., 
1995).   
 
With gathering evidence the story of antigen specifics has become more 
complicated.  Whilst myelin proteins continue to be implicated as a target for 
immune system activity, other antigens such as αB crystalline (Ousman et al., 2007) 
and neurofascin (Mathey et al., 2007) have been identified as important in tissue 
targeting and destruction.  In recent years it has also become clear that the 
immunological interplay is not as simple as first thought.  Evidence countering the 
central role of CD4+ cells and broadening the repertoire of implicated 
immunological cells includes; MHC class 1-restricted, CD8-positive cells are the 
predominant cell type found in active MS lesions (Babbe et al., 2000); lymphocytes 
may not be present in early demyelinated lesions; perivascular inflammatory cuffs 
can occur in normal appearing white matter (Barnett and Sutton, 2006).  In 
addition, therapies such as anti-interleukin 12p40 that targeted CD4+ T cell function 
have proved ineffective in clinical trials (Segal et al., 2008).  It has also recently been 
discovered that inflammation in EAE is driven by an alternative T-lymphocyte 
subtype that secretes interleukin 17, effectively disrupting the blood-brain barrier 
and allowing neurotoxic Th17 cells direct access to the CNS (Kebir et al., 2007). 
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These novel insights have prompted further interrogation of the underlying 
immunology of the condition and redirected focus to alternative cell types that may 
contribute to the pathogenesis of MS.  Previously unknown contributors to the 
disease process include the Th17 cells (producing IL 17) discussed above, B cells, 
CD8+ cells and both CD4+ and CD8+ T-regulatory cells (Kasper and Shoemaker, 2010).  
Other effector populations include CD56+ natural killer cells, invariant NK cells and 
stem cells (Kasper and Shoemaker, 2010). 
 
The plethora of immune cells involved in the initiation of inflammation accumulate 
at the site of myelin injury and through expression of pro-inflammatory cytokines 
recruit resident microglia.  These cells are activated, delivering tissue necrosis factor 
α at the opsonised oligodendrocyte-myelin complex resulting in cell death and 
myelin destruction (Zajicek et al., 1992).  Lesions are associated with axonal injury, 
even transection and associated Wallerian degeneration, and as the disease 
becomes progressive there is radial expansion of areas of white matter injury. 
 
Axons receive trophic support from oligodendrocytes.  Unsurprisingly, even early in 
the disease course, axonal damage is detectable in the lesions of MS (Trapp et al., 
1998).  As well as terminal axonal ovoids (an indicator of axonal transection) in 
active and other lesions, axonal loss is identified in normal appearing white matter 
and the unmyelinated cells of the retinal nerve fibre layer.  Mechanisms postulated 
to underlie these findings in apparently ‘normal’ or unmyelinated tissue includes 
mitochondrial dysfunction secondary to oxidative and nitrative stress (Bolaños et 
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al., 1997) - the apparent size-dependent loss of axons in NAWM supports disruption 
of energy supply as a likely mechanism (Stys, 2005).  As outlined elsewhere, it is the 
cumulative loss of axons, eventually exhausting the CNS functional reserve that 





We have earlier briefly discussed the natural progression of MS and the 
transformation from repeated inflammatory-predominant episodes with complete 
or near-complete recovery of symptoms to one of progressive clinical decline as a 
result of cumulative axonal damage in an environment of dwindling trophic 
support.  Attempts at disease modification have thus far focussed on one of two 
approaches to the inflammatory component of the condition; immune stimulation 
on the basis that either persistent viral infection or immunoregulatory defect was 
central to disease pathogenesis; and immuno-suppression, initially using agents 
that were largely non-specific.   
 
Several studies using immunostimulants were pivotal in developing our 
understanding of disease mechanisms, providing unambiguous evidence that 
clearly redirected research efforts.  Of particular note was a study of interferon-γ 
(Panitch et al., 1987) which demonstrated excess disease activity following 8 
injections over a 4 week period in association with an increase in MHC class II-
positive circulating lymphocytes.  Efforts were subsequently redirected towards 
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attempting to ameliorate inflammatory activity in increasingly specific ways.  
Recommendations from the interferon-γ trial authors included trials of the 
interferon-γ inhibitors interferon-α and interferon-β, subsequently the bedrock of 
disease modification for the next decade and more. 
 
Conventional disease-modifying therapy in multiple sclerosis has focused on 
attempting to suppress or modify the inflammatory component of the disease 
process.  The argument is made that preventing or reducing the frequency of 
discrete inflammatory events will in theory delay the point at which the patient’s 
burden of disease facilitates entry into the progressive phases of the condition in 
which inflammation is not prominent and immunotherapies have no theoretical 
beneficial role to play.  Whilst the debate remains keenly contested in certain 
quarters, these predictions have not been realised in the most comprehensive 
analyses of disease-modifying drugs that have thus far been performed (Mantia et 
al., 2013; Shirani et al., 2012; Tur et al., 2011).  These results have however 
informed concepts of the disease with prevalence given to the theory of a threshold 
of inflammatory-mediated injury beyond which neurodegenerative mechanisms 
are the primary pathology.   
   
The first licensed treatment for disease modification in MS in the EU was interferon-
β 1b, awarded in November 1995 on the basis of a single pivotal study (1993; 1995) 
which demonstrated a reduction in annual exacerbation rate from 1.27 in the 
placebo group to 0.84 in the 8-MIU treatment group.  The reduction of 
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inflammatory activity on MRI imaging of the brain heightened the impact of the 
early study.   
 
The next EU marketing licence was awarded to glatiramer acetate a year later after 
demonstration of a 29% reduction in annualized relapse rate compared with 
placebo (Johnson et al., 2001).  Similar results were seen in the pivotal trials of 
interferon-β 1a (Avonex, Rebif) (1998).  Both were granted licenses towards the end 
of the 1990’s.  The introduction to clinical practice of these medications was 
somewhat erratic and incoherent due in part to an expectant and hitherto 
underserved patient population and aggressive marketing and promotion by the 
drug’s manufacturers.  Several monitoring schemes were established to try and 
assess long-term efficacy and in some instances facilitate the use of expensive drugs 
that were subject to government rationing (such as the UK risk sharing scheme).  
These have confirmed the initial findings of an approximately 30% reduction in 
relapse rate and provided further evidence of long-term safety (Ford et al., 2010; 
Palace et al., 2015).  None however have thus far demonstrated any convincing 
evidence of long-term modification of disease course and disability accrual.  The 
mechanisms of action of beta interferons that are thought relevant in the context 
of MS include inhibition of T-cell activation, modulation of anti- and pro-
inflammatory cytokines and restriction of aberrant T-cell migration – though the 
precise mechanism is not definitively established. 
 
Alongside glatiramer acetate (which targets T-cell peptide binding) several drugs 
that target T-cell populations have been trialled with the recent emergence of 
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monoclonal antibodies that are able to target single components of the immune 
system.  Alemtuzumab was the first humanised chimeric monoclonal antibody to 
be produced.  It targets CD52 which is present on all lymphocytes and some 
monocytes, subsequently activating complement and mediating cytotoxic 
mechanisms leading to effective depletion of lymphocyte populations (Xia et al., 
1993).  Trial datasets have also suggested neuroprotective effects of the medication 
(Jones et al., 2010).  A phase II clinical trial demonstrated significant reduction of 
relapse risk and sustained accumulation of disability of >70% compared to 
interferon-β 1a (Coles et al., 2008).  Although the 5 year follow up showed 
maintenance of the reduced risk of sustained disability accumulation (Coles et al., 
2012), subsequent phase III studies have not replicated the finding (though this may 
be explained by atypical performance of the control group (Cohen et al., 2012a)). 
 
Natalizumab is a humanised monoclonal antibody that targets lymphocyte α4β1-
integrin, preventing interaction with VCAM-1 on endothelial cells and consequently 
inhibiting migration across the blood-brain barrier.  The pivotal trial of Natalizumab 
demonstrated 68% reduction in relapse rate compared with placebo with reduction 
of the risk of sustained progression of disability by 42% over two years (Polman et 
al., 2006).   
 
Both of the monoclonal antibodies currently licenced for the treatment of MS have 
had significant issues with adverse side effects; Natalizumab with the development 
of progressive multifocal leukoencephalopathy (Bloomgren et al., 2012) and 
Alemtuzumab with the development of a number of autoimmune diseases 
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including idiopathic thrombocytopenic purpura and Grave’s disease (Cossburn et 
al., 2011).  When compared with the interferon’s side-effect profile, these potential 
complications limit use which is restricted to those with more aggressive disease. 
 
In the last few years several oral agents have been licensed for use in RRMS – these 
are all immuno-modulatory agents with varying degrees of potency and side-effect 
profiles.  The first to be licensed was Fingolimod (a sphingosine 1-phosphate agonist 
which prevents lymphocyte egress from lymph nodes) which received 
recommendation as a second-line agent in English clinical guidelines.  In pivotal 
studies relapse rate was reduced by >50% compared with placebo (Kappos et al., 
2010).  As with the monoclonal antibodies, adverse events were more prominent 
than seen with older ‘injectables’ with mortalities in trial participants due to 
disseminated viral infection (Cohen et al., 2010).  More recently, dimethyl 
fumarate, a fumaric acid ester whose actions include reduction of oxidative stress 
and alteration of chemokine/cytokine profile (producing an anti-inflammatory 
effect) has been licensed for use in RRMS.  It has been shown to reduce relapse rate 
by 48-53% compared to placebo (Gold et al., 2012).  There have been reported 
cases of PML in the context of its use (though none during treatment for MS) (Ermis 
et al., 2013).  The third oral medication to receive a license for the treatment of 
RRMS is Teriflunomide, a selective immunosuppressant that ameliorates 
lymphocyte proliferation by inhibition of dihydroorotate dehydrogenase, reducing 
pyrimidine synthesis.  The precise mode-of-action of the medication in the context 
of MS remains to be definitively established.  Teriflunomide represents the active 
element of the prodrug leflunomide which has been used for some time in 
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rheumatoid arthritis.  In RRMS it was shown to reduce annual relapse rate by 31% 
(O'Connor et al., 2011) and is now licensed as first line therapy.   
 
 
Inflammation vs neurodegeneration 
 
All licensed disease modifying drugs used in RRMS have shown throughout their 
development, repeated and in certain circumstances, profound suppression of 
inflammatory activity when observed in-vivo through the medium of magnetic 
resonance (MR) imaging.  Therapeutics have become increasingly specific in their 
ability to suppress ever narrower elements of the immune system.  Despite this, 
none of the trials have thus far been able to demonstrate any sustained effect on 
long-term disability accumulation.  This has informed and served to refocus the 
debate surrounding disease mechanisms and the relationship between 
inflammation and axonal loss which underlies the development of long-term 
disability accrual. 
 
There are four theoretically possible explanations for the relationship of 
inflammation and neurodegeneration; that inflammation is the sole pathological 
mechanism; that neurodegeneration is the primary pathology with secondary or 
reactive inflammatory changes as a result; that the two processes both occur 
completely independently; or that inflammation is the index event with 
neurodegeneration the result of the attainment of a (pathologically lowered) 
threshold beyond which axonal integrity cannot be maintained.  Evidence from 
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natural history and therapeutic studies have both served to inform the debate and 
illuminate the role of axonal loss in the progressive variants or stages of the disease.   
 
Evidence from natural history studies; 
This includes work analysing the Rennes MS database that suggested two distinct 
stages of disability progression within MS (Leray et al., 2010).  Using Kurtzke’s 
Expanded Disability Status Scale the study analysed time to reach Disability Status 
Scale (DSS) 3 (mild-moderate disability but fully ambulant) - phase 1, and time from 
DSS 3 to DSS 6 (requirement of unilateral assistance to mobilise) - phase 2, in both 
relapsing remitting and progressive onset disease.  The study established that phase 
2 duration was almost identical irrespective of the duration of phase 1.  
Kremenchutzky and colleagues (Kremenchutzky et al., 2006) chose to group 
patients into those with secondary progressive disease, single relapse at onset or 
no relapses at onset ie primary progressive disease, and identified a similar speed 
of progression of disability in all 3 groups.  The researchers concluded that the 
stereotyped nature of the progressive phase suggests common functional 
differential susceptibility to a neurodegenerative process.  Furthermore they 
highlighted the prevalent distal corticospinal tract dysfunction that underlines 
much of the disability accrual in progressive disease and hypothesised that this may 
represent a central dying-back axonopathy which is independent of plaque location 
or burden.  They include in their conclusions the possibility that the 




Confavreux and Vukusic used similar natural history data from the Lyon MS cohort 
to draw slightly different conclusions (Confavreux and Vukusic, 2006a).  They 
focused on age at attainment of disability milestones rather duration of disease and 
concluded that prognosis in MS, regardless of disease phenotype, is to an extent, 
age-dependent.  They hypothesised that alongside inflammatory and degenerative 
mechanisms there may be accelerated age-related mechanisms contributing to the 
disability seen in progressive disease.  In more wide-ranging data published 
contemporaneously (Confavreux and Vukusic, 2006b), the same authors used data 
from all forms of the disease to draw ambitious conclusions about a unifying 
concept of the disease which they describe as a ‘position of complexity rather than 
true heterogeneity.’  Essentially they believe the different disease phenotypes to 
be variants of the same disease processes; relapsing–remitting disease can be 
regarded as multiple sclerosis in which insufficient time has elapsed for the 
conversion to secondary progression; secondary progressive forms as relapsing–
remitting multiple sclerosis that has ‘grown older’; and progressive from onset 
cases as multiple sclerosis ‘amputated’ from its usual preceding relapsing–remitting 
phase. 
 
Evidence from therapeutic studies; 
The predominant contemporary doctrine regards the inflammatory component of 
the disease as the index or primary event (though as discussed above this concept 
is challenged in some quarters).  Treatment of the underlying disease process, so-
called disease modification, has universally centred on manipulation of the immune 
system and inflammatory response.  Evidence for long-term impact on disability 
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progression has not yet been produced.  Whilst this is in part due to limitations on 
the duration of therapeutic studies in the context of a chronic disease that has a 30-
plus year natural history, this failure does leave room for doubt about the likely 
avenues of treatment that will hopefully one day result in a cure for the disease.   
 
The disconnect between suppression of inflammation and clinical progression is 
notably demonstrated by studies of anti-CD52 monoclonal antibody in MS.  Early 
trials of the antibody were performed in patients with secondary progressive 
disease (Coles et al., 1999); the study demonstrated almost complete cessation 
(>90%) of MRI evidence of inflammatory activity for 18 months (replicating findings 
of earlier proof-of-concept studies (Moreau et al., 1994)) in the progressive cohort, 
together with reduction of relapse rate from 0.7 per patient per year to 0.02 per 
patient per year at a mean follow up of 6.7 years.  Effective suppression of 
inflammation was again demonstrated (T1 lesion volume and proton density) on 
follow up scans a further 5.8 years later.  Despite the suppression of inflammatory 
activity, disability continued to increase by 0.2 EDSS points per year with associated 
brain atrophy attributable to axonal loss demonstrated with MRI spectroscopy.  
Interestingly, deterioration was correlated with inflammatory disease activity at 
baseline.  Two patients in the study showed continuing cerebral atrophy despite 
clinical stability.  The findings suggested that axonal degeneration is conditioned by 
prior inflammation and proceeds despite its effective suppression, and that this is 
responsible for disability accrual.  The authors concluded that results supported the 
hypothesis that immunosuppressive treatment must be given early in the disease 
course ‘before the consequences of inflammation are irretrievably established’.  In 
32 
 
subsequent work the same investigators administered Campath-1H (anti-CD52 
monoclonal antibody) to 22 patients with early (total of 60 patient years pre-
treatment) RRMS (Coles et al., 2006).  In those in whom EDSS had improved at 1 
year, the changes were sustained at 24 months (mean EDSS -1.4); the treatment 
had effectively stabilised EDSS.  These results are in stark contrast to the findings in 
SPMS and prompted the authors to speculate that early treatment to stop 
inflammatory demyelination may prevent long-term axonal degeneration. 
 
 
Alternative therapeutic strategies 
 
In summary, trial results make it clear that inflammation is key in the establishment 
of the demyelinated plaque, and appears to condition the axonal loss underpinning 
progressive disability.  In theory, the cessation of inflammation prior to initiation of 
the cascade of processes that lead to loss of axonal integrity may prevent disability, 
but the ability of powerful immunosuppression to achieve this remains to be 
established.  It is also important to factor in too, that currently available 
therapeutics that most effectively terminate inflammatory activity (with Campath-
1H) comes at a cost of potentially significant side effects (Cossburn et al., 2011).  A 
number of additional approaches are needed if we are to start to address the as yet 
unmet therapeutic needs of this cohort of patients and prevent the 
neurodegeneration that most contributes to the burden of disease.  This includes 
but is not restricted to; 
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1) Prevention of diffuse microglial activation and on-going insult to the 
axon-glial unit 
2) Axonal protection against  
a. acute injury 
b. chronic degenerative processes 
3) Enhancement of repair mechanisms, particularly in the context of 
myelin 
4) Promotion of plasticity 
5) Promotion of axonal regeneration 
 
The solution to each of these individual problems is unlikely to have a meaningful 
impact on progress in the search for a cure (supported by the absence of 
identifiable single gene defects in aetiological explanations), but in combination or 
in total, may bring success to swelling research efforts. 
 
 
Cell therapy for Multiple Sclerosis 
 
The failure of conventional therapy to significantly alter the disease course in 
Multiple Sclerosis has already led investigators (and charlatans) to explore 
alternative therapies – some with very little in the way of theoretical or proven in-
vitro or in-vivo mechanistic explanation.  Among the scientific community, cellular 
therapies have gained prominence.  Whilst the proposed mechanisms of 
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therapeutic effect have shifted somewhat, translational work is now beginning to 
explore undoubted pre-clinical promise. 
 
The initial mechanisms by which it was thought exogenous stem cells would confer 
their treatment effect in MS was through replacement of tissue lost or damaged.  
This was felt to be particularly pertinent to replacement of myelin and 
oligodendrocytes (the target of inflammation in MS); in contrast, the replacement 
of neurons and axons and their innumerable connections would appear to provide 
an infinitely more complex, possibly even insurmountable problem.  These early 
hopes were driven by several influential papers including the work of Blakemore 
and colleagues who demonstrated successful remyelination of demyelinated CNS 
lesions using direct implantation of exogenous sciatic Schwann cells (Blakemore, 
1977).    With hindsight this approach (particularly in the context of MS) appears 
somewhat misguided with efforts now beginning to focus on more widespread and 
varied protective and reparative effects of cellular therapy.  We will begin by 
looking at the initially proposed modes of action, particularly remyelination and the 





Early work by Bunge and colleagues (BUNGE et al., 1961) provided some of the first 
detailed studies of the mature mammalian brain’s ability to remyelinate following 
experimental lesioning.  The human brain’s capacity for remyelination was first 
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discovered over 40 years ago by Perier and Gregoire who identified glial processes 
wrapping around axons at the periphery of lesions in multiple sclerosis (MS) post-
mortem tissue (Périer and Grégoire, 1965). These findings were supported by the 
realisation that shadow plaques represent areas of remyelination (Prineas and 
Connell, 1979) and also by their subsequent electron microscopic evaluation.  
Although at first this remyelination was thought to be sparse and largely 
functionally ineffective, subsequent data has shown that remyelination occurs 
much earlier than first thought (Merkler et al., 2006) and far more extensively - 
white matter lesions have been shown to have high rates of remyelination with only 
5% being completely demyelinated and an average lesion remyelination extent of 
47% (Patani et al., 2007).  Work by Albert and colleagues showed similar results and 
went further in demonstrating higher rates of remyelination in cortical lesions 
(present in 29/30 patients with chronic disease) compared with white matter 
(evidence of remyelination in more than 2/3 of lesions) (Albert et al., 2007).  The 
origin of new myelin formation has remained obscure though it was recognised 
early on that, as might be expected, most is achieved through cells of 
oligodendrocyte lineage.  
 
Cells that have been demonstrated to affect a degree of repair in demyelinated 
tissue include oligodendrocyte precursor cells and endogenous neural stem cells.  
Picard-Riera and colleagues used lysolecithin-induced demyelination in a murine 
model of MS and documented neural progenitors of the sub-ventricular zone 
migrating to periventricular white matter and giving rise to both astrocytes and 
oligodendrocytes within lesioned tissue (Picard-Riera et al., 2002).  
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Oligodendrocyte precursors have been identified in both normal brains and in MS 
post-mortem tissue (Scolding et al., 1998).  These cells have been shown to 
proliferate (Redwine and Armstrong, 1998) and migrate (Carroll and Jennings, 
1994) in response to demyelination.  They also show several morphological 
adaptations (Levine et al., 2001) and changes to patterns of gene expression (Fancy 
et al., 2004) (which play a crucial role in the embryological differentiation of 
oligodendrocytes) in response to CNS inflammation.   
 
Further characteristics of endogenous remyelinating cells were elucidated by the 
work of Snethen et al (Snethen et al., 2008) who examined the expression of the 
neural stem cell markers Nestin and Mushashi (found on early neural progenitors) 
in MS post-mortem tissue.  Nestin-positive cells were identified in MS lesions in high 
numbers, and were also identified within normal appearing white matter.  
Mushashi co-labelling was evident in almost 90% of Nestin-positive cells in lesions, 
providing further confirmation of the presence of neural precursor cells in lesioned 
areas of the brain. Furthermore, within lesions a high proportion of astrocytes co-
expressed nestin; and nestin-positive cells also expressed oligodendrocyte 
precursor cell markers, though in small numbers.  Evidence was also seen of Nestin-
positive cells colabelling with doublecortin, a marker of immature neuronal lineage 
cells, lending weight to the possibility that a degree of axonal regeneration might 
also be achieved by endogenous stem cells.  Despite the presence of functionally 
significant numbers of progenitor cells, remyelination is frequently incomplete.  
Some of the reasons for this functional deficit have been identified (hyaluronan 
accumulation and expression of PSA-NCAM) and provide further potential 
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therapeutic targets (Fancy et al., 2010).  Additional rationale for the failure of 
remyelination include ageing of the progenitor cell population, exposure to direct 





One of the first fundamental questions that was posed as the science behind re-
growing elements of the injured CNS was approached was of course which cells 
would be able to perform such feats.  Given that most endogenous repair is carried 
out by oligodendrocyte progenitor cells, they appeared the most logical source of 
cells for replacement therapy.  Although they can be isolated from the adult human 
brain (Scolding et al., 1995) and proliferate in-vitro, the numbers involved are 
relatively low (Roy et al., 1999) and they show only limited migration in response 
to CNS tissue injury (Franklin et al., 1997).  Given these logistical challenges, 
alternative sources of remyelinating cells were considered including but not limited 
to Schwann cells (as originally used by Blakemore), olfactory glia from the olfactory 
bulb, xenogenic transplanted cells and human stem cells.  Stem cells have many 
properties that made them clear frontrunners in the search for an effective 
candidate - the most fundamental of which is their multipotency.  Stem cells are 
attached to basal lamina and are able achieve asymmetric mitosis, generating both 
progenitor cells and self-renewing.  In mature organisms these cells are central to 
tissue repair and regeneration and as such are particularly resilient in tissue-
injurious environments – one remarkable example of this is the isolation of such 
38 
 
cells from post-mortem tissue (Mayer et al., 2005).  Other properties of theoretical 
value include an apparent tropism for areas of tissue injury and their mitotic 
potential to generate vast numbers of daughter cells whose fate could be directed 
along desired lineages.   
 
Broadly speaking stem cells can be either embryonic or adult-derived, though the 
category of induced stem cells has been introduced in the last 10 years.  Embryonic 
stem cells (ESCs) are found in the inner cell mass of blastocysts and were first 
isolated from mouse embryos in 1981 (Evans and Kaufman, 1981).  Human ESCs 
have also been isolated (Thomson et al., 1998) and differentiated along neuronal 
lineages (Carpenter et al., 2001).  The technology also exists to isolate neural 
precursor cells directly from embryonic tissue (Reynolds and Weiss, 1996).  Whilst 
benefit has been shown in animal models of other neurological conditions (Studer 
et al., 1998) the practical challenges in translating their use to in-human therapeutic 
studies are largely prohibitive (Armstrong et al., 2000).  The use of embryonic stem 
cells comes with two clear problems; the first is the propensity of the cells to form 
teratomas (Bjorklund et al., 2002) and the second, the ethical implications of 
harvesting cells from a pre-implantation blastocyst (or in the case of neural 
precursor cells from embryonic tissue) which has the potential to develop 
into/already is an individual human being.  Translational use of these cells has 
therefore been limited.   
 
The ethical issues of ESCs (and indeed of therapeutic human cloning) have been 
somewhat circumvented by the development of techniques to reverse adult cell 
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differentiation to produce induced pluripotent stem cells (iPSCs).  iPSCs were first 
generated by Takahashi and Yamanaka in 2006 (Takahashi and Yamanaka, 2006); 
the technique used just four transcription factors (Oct3/4, Sox2, c-Myc, and Klf4) to 
generate pluripotent stem cells from adult mouse fibroblasts.  This work was 
followed by the generation of human iPSCs by both Yamanaka (Takahashi et al., 
2007) and a group at the University of Wisconsin-Madison (Yu et al., 2007).  iPSCs 
have almost identical properties to ESCs including their morphology, self-renewal, 
proliferation, gene expression, and ability to differentiate into all three germ cell 
layers both in vitro and in the context of teratoma formation.  As with ESCs 
however, safety concerns have limited translational work and their current role is 
primarily in modelling disease for the purposes of laboratory study.  Mouse iPSCs 
have been used to generate neural precursor cells and OPCs (Czepiel et al., 2011) 
and have been demonstrated to ameliorate pathological and clinical features of 
disease in EAE in mice when delivered intrathecally (Laterza et al., 2013).  
Interestingly the effects were found to be due to neuroprotective effects rather 
than direct integration and tissue repair.  A degree of the neuroprotective effect 
was conferred through leukaemia inhibitory factor (LIF) which promotes 
endogenous remyelination.  Human iPSC-derived OPCs were shown by Wang and 
colleagues to myelinate a myelin basic protein-deficient shiverer mouse model 
when implanted neonatally (Wang et al., 2013).  The efficiency of myelination seen 
with the iPSC-dervied OPCs was higher for that seen with ESC-derived progenitors.  
Transplantation of allogenic OPCs from whichever source is fraught with problems 
related to compatibility and rejection, a particular concern in the context of the 
aberrant immune environment encountered in MS (Keyoung and Goldman, 2007).  
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Additional practical difficulties arise from the problem of ‘epigenetic signature’, a 
resident epigenetic profile that encourages iPSCs to differentiate down their 
original lineage (Bar-Nur et al., 2011).  Whilst iPSCs have the distinct advantage of 
being genetically identical to the donor individual, the functionality of OPCs derived 
from iPSCs in individuals with MS or other disease remains to be determined. 
 
The other principal category of stem cells are those derived from a mature (usually 
mammalian in the context of biomedical research) organism – termed adult or 
somatic stem cells.  These are linage-restricted cells resident in multiple tissues in 
the adult organism, able to effect repair and regeneration in response to natural 
cell turnover or cell loss in the context of trauma or disease.  The presence of such 
cells in humans, especially in tissues with a high turnover such as skin or blood was 
first predicted at the beginning of the 20th century by the Russian Histologist 
Alexander Maximow who developed the  unitarian theory of haematopoiesis.  Adult 
stem cells are numerically infrequent cells that reside within tissues within the 
mature, adult organism.  Whilst showing multipotency, and able to replicate 
asymmetrically to both self-renew and produce fate-restricted progenitors with 
more limited proliferative capacity, these cells are thought to be restricted to the 
lineage of their organ of origin.  Haematopoietic stem cells have been the most 
widely studied of human somatic stem cells, with over 50 years of detailed 
laboratory characterisation and substantial safety data acquired through what has 
become routine clinical use, primarily in the treatment of malignant haematological 
disease.  Adult stem cells are found in tissues throughout the body including in the 
brain (Arsenijevic et al., 2001; Weiss et al., 1996).  From the perspective of tissue 
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replacement, hese cells have also successfully been used to generate 
oligodendrocyte precursors, a prerequisite for effective remyelinating potential 
(Zhang et al., 2000).   
 
 
Bone marrow-derived Adult Stem Cells 
 
Bone marrow contains a readily accessible supply of a number of adult stem cell 
populations that are increasingly being exploited in wide-ranging medical 
conditions including myocardial infarction (Núñez García et al., 2015), liver cirrhosis 
(Margini et al., 2014), osteoarthritis (Marmotti et al., 2014), several respiratory 
diseases including pulmonary hypertension, COPD and asthma (Jones and Rankin, 
2011) and degenerative eye disease (Mead et al., 2015); indeed bone marrow-
derived stem cells are currently being explored as potential therapy in diseases 
affecting the majority of the human body’s organs.  The so-called bone marrow 
stem cell compartment consists of a number of cell populations, traditionally 
thought to include haematopoietic stem cells, mesenchymal or stromal cells and 
endothelial progenitor cells.  As our understanding develops and more cell types 
are characterised it is becoming apparent that differences between cell subsets are 
much more nuanced than previously thought with the suggestion that several 
populations that have been described in the literature with varied isolation 
techniques do in fact represent very similar or even overlapping sub-populations.  
These include multipotent adult progenitor cells (MAPCs) (Serafini et al., 2007), 
marrow-isolated adult multilineage inducible (MIAMI) cells (D'Ippolito et al., 2004) 
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and multilineage-differentiating stress-enduring (MUSE) cells (Wakao et al., 2011).  
Very small embryonic-like stem cells (VSELs) are another cell type that can be 
isolated from the bone marrow niche and are argued by some to account for much 
of the multipotency attributed to various bone marrow-derived cell subsets 
(Ratajczak et al., 2014). VSELs can be isolated by flow cytometry using a series of 
cell markers (Sca-1+; CD45-; lin-) and have many properties in common with 
pluripotent embryonic stem cells including open-type euchromatin DNA, a  large 
nuclear: cytoplasmic ratio and expression of several embryonic lineage markers 
including stage-specific embryonic antigen 1 (SSEA-1), Oct-4, Nanog, and RNA 
exonuclease 1 homolog (Rex1) (Kucia et al., 2005).  These and other discoveries 
have prompted efforts to start to try to reclassify and categorise populations of 
stem cells residing in the bone marrow stem cell compartment (Zhang and Huang, 
2012).  Broadly speaking the cells can be classified as haematopoietic or non-
haematopoietic stem cells with further delineation of the non-haematopoietic 
population yet to gain consensus.  
 
Haematopoietic stem cells; 
The restoration of haematopoiesis following myeloablative therapy by 
haematopoietic stem cells is the most obvious therapeutic example of the ability of 
somatic stem cells to restore function through replacement of tissues lost or 
damaged and is in routine clinical use in haematology clinics around the world.  
Haematopoietic stem cells were traditionally thought to express CD34, CD45 and 
Thy-1 with absence of multiple markers of lineage commitment (lin-).  It has become 
apparent with time, however, that HSCs are a much more heterogeneous 
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population than first thought (Eaves, 2015).  Current isolation techniques including 
using physical and biochemical (enzymatic) properties along with patterns of 
surface markers (specifically signalling lymphocyte activation molecules or SLAM 
markers) gives rise to demonstrably different types of long-term repopulating cell 
phenotypes with distinct repopulating kinetics (Eaves, 2015).  Clinical use of HSCs 
for the purposes of reconstitution of the haematopoietic system does not require 
separation of these cell subsets which are collected directly from red bone marrow 
or from G-CSF-mobilised peripheral blood.   
 
Endothelial progenitor cells; 
Endothelial progenitor cells are a population of cells that have the capacity to 
migrate to the peripheral circulation and differentiate to form mature endothelial 
cells.  They express a number of cell markers including CD34, CD133, and vascular 
endothelial growth factor (VEGF)-receptor 2.  Maturation is associated with loss of 
CD133 expression and expression of CD31, vascular endothelial cadherin and von 
Willebrand factor (Hristov et al., 2003; Hristov and Weber, 2004).  Their role in 
angiogenesis has made them attractive candidates for use in potential therapies for 
a number of ischaemic conditions including but not restricted to myocardial 
infarction (Henning, 2011), enhancement of vascular graft endothelialisation (Goh 







Mesenchymal stromal cells; 
Mulitpotent mesenchymal stromal cells (variously referred to as mesenchymal 
stem cells and marrow stromal cells) were first isolated by Friedenstein and 
colleagues in the 1960s when osteogenic progenitor cells with fibroblast-like 
morphology were isolated from the bone marrow of adult rats (Friedenstein et al., 
1966).  The group proceeded to characterise in more detail what were termed 
colony-forming unit-fibroblasts but it wasn’t until 1991 that the term Mesenchymal 
Stem Cell appeared in the literature.  The varying nomenclature is something of a 
misnomer; the cells are neither mesenchymal (they are not thought to generate 
haematopoietic cells under normal in-vivo conditions), nor are they purely stromal 
(connective role supporting active cells within the residing tissue).  The multitude 
of properties that these cells have been found to possess, with particular emphasis 
on tissue repair (suggested by some to be their primary function) are discussed in 
more detail below.  These spindle–shaped cells make up approximately 0.01-
0.001% of nucleated bone marrow cells (Xiao et al., 2015) and can be manipulated 
to differentiate into cells of adipogenic, osteogenic and chondrogenic lineage 
(Pittenger et al., 1999).  The difficulty associated with varying terminology and 
isolation methods being reported in the literature led the International Society for 
Cellular Therapy Mesenchymal and Stem Cell Committee to first clarify the 
nomenclature (Horwitz et al., 2005) and subsequently to establish minimum criteria 
for the isolation and identification of MSCs, enabling standardisation of a 
fragmented field (Dominici et al., 2006).  The criteria consisted of;  
1) Isolation by plastic-adherence under standard culture conditions 
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2) Expression of specific cell surface markers: express (≥90%) CD105, CD73 
and CD90: negative (≤2%) for CD45, CD34, CD14 or CD11b, CD79 or CD19 
and HLA-DR 
3) Ability to differentiate into osteoblasts, adipocytes and chondroblasts in 
vitro.   
Following initial identification in bone marrow, MSCs were subsequently discovered 
in many other tissues; notably adipose tissue (Zuk et al., 2001) and dental pulp 
(Bojic et al., 2014) – indeed it is becoming increasingly accepted that MSCs reside 
in most if not all tissues in the body (da Silva Meirelles et al., 2006).   
 
Interest in MSCs in the field of MS and other neurodegenerative diseases was first 
piqued at the turn of the century when it was realised that the cells could be 
manipulated to differentiate into cells of neuroectodermal lineage with obvious 
implications for the therapeutic strategy of tissue replacement (Sanchez-Ramos et 
al., 2000).  The identification of rapid and widespread transdifferentiation and 
integration of donor-derived bone marrow cells in the brains of mice lent further 
support to the potential of the science.  Cells were detectable in the brain of the 
recipient animal after just 3 days with cells eventually detectable throughout the 
brain including the cortex, hippocampus, thalamus, brain stem, and cerebellum 
(Eglitis and Mezey, 1997).  Cells of bone marrow origin were quite logically then 
hypothesised to contribute to spontaneous tissue repair in the central nervous 
system with obvious implications for a number of conditions (Kørbling and Estrov, 
2003).  Further evidence of a potential physiological role in neural tissue repair 
came from studies of post-mortem brain tissue from patients given sex-
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mismatched bone marrow transplants, where ‘transgender’ astrocytes and 
neurons constituted 1% of hippocampal neurons/astrocytes (Cogle et al., 2004).   
 
 
Alternative mechanisms of MSC activity 
 
Through careful and repeated study of murine models of MS (principally extrinsic 
allergic encephalomyelitis) and its treatment with MSCs it has become apparent 
that the cells provide neuroprotection and can ameliorate disease without 
significant neural differentiation (Gordon et al., 2008), with focus therefore shifting 
to alternative mechanisms of therapeutic effect.   
 
Cell replacement; 
It is still possible that the cells do achieve a degree of cellular replacement but the 
extent to which this is functionally relevant remains to be established.  Whilst the 
significance of processes including transdifferentation, transdetermination, and 
dedifferentiation have not been advanced, there is emerging evidence of fusion as 
a potential mode of tissue repair both in neural tissue (purkinje cells of the 
cerebellum) and others including cardiomyocytes and hepatocytes (Alvarez-Dolado 
et al., 2003).  Fusion of human MSCs with host rodent neural cells has been 
documented in-vivo (Kemp et al., 2011), with evidence that other marrow-derived 
cells fuse in response to inflammation and immune-system activation, clearly 
relevant in the MS CNS environment (Johansson et al., 2008).  This study also 
identified cell fusion occurring at much higher frequency than previously thought 
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(10-100 fold) and whilst the functional significance of such fusion remains 
unanswered in the context of CNS disease, cell fusion has been demonstrated to 
restore liver function in mice with lethal recessive liver disease (Vassilopoulos et al., 
2003).   
 
Heterokaryon formation has been identified in the brains of patients with MS 
(Kemp et al., 2012) - binucleate heterokaryons were identified at higher frequency 
in the cerebellum of 6 patients with MS compared with controls.  Further 
mechanism of potential therapeutic benefit in the context of cellular fusion include 
the discovery that MSCs are able to  temporarily fuse with and transfer 
mitochondria to murine alveolar epithelia in the context of acute lung injury, with 
functional significance evident through increases in levels of intracellular ATP (Islam 
et al., 2012).  The precise role of cellular fusion remains to be fully established; it 
could represent a mechanism by which healthy nuclei or genes are delivered to 
damaged or ageing cells, effectively protecting against degeneration, and 




Immune system modulation with suppression of destructive inflammatory activity 
and enhancement of reparative elements would have obvious implications in the 
treatment of MS.  MSCs have been shown to have effects on both the innate and 
adaptive immune systems, inducing profound inhibitory effects on a number of 
cellular components of the immune system including T cells, B cells, dendritic cells 
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and natural killer cells (Uccelli et al., 2007) and have been utilised in a number of 
autoimmune conditions including graft versus host disease and inflammatory 
bowel disease (Bernardo and Fibbe, 2012).  Significant abrogation of disease 
severity in animal models of MS has been achieved using human MSCs (Gordon et 
al., 2008) and translational studies are in progress.  It should be noted that in the 
study by Gordon et al the beneficial effects of MSCs were seen without significant 
CNS infiltration or indeed integration.  Inflammation contributes to axonal loss and 
its abrogation by MSCs has been demonstrated in the animal model EAE to preserve 
axonal tissue (Zhang et al., 2006).  Whilst immunosuppressive effects of MSCs 
would clearly be desirable and would in theory contribute to therapeutic activity, it 
is not thought to be their principal mode of action and is likely to be of a much lesser 
order than levels achieved using powerful contemporary agents that target single 
cell markers (such as alemtuzumab) or even smaller but eloquent molecular 
components of the immune system such as NLRP3 (The NOD-like receptor (NLR) 
family, pyrin domain-containing protein 3) (Coll et al., 2015). 
 
Neuroprotection; 
With the accumulation of research data, it has become clearer that the probable 
principal mechanism of functional benefit of bone marrow-derived stem cells is 
paracrine activity which provides powerful neuroprotective effects.  This is 
achieved via a number of mechanisms including anti-oxidant activity, provision of 





Amelioration of oxidative/nitrative stress; 
Reactive oxygen and nitrogen species are generated as part of cells’ normal 
physiology.  Overproduction of ROS or a failure of antioxidant mechanisms can lead 
to damage to lipids, proteins and nucleic acids in cells and mitochondria, potentially 
resulting in cell death.  There is a constant exposure to low levels of these 
oxidative/nitrative species in the normal CNS at levels which can easily be dealt with 
by inherent repair and protection mechanisms.  In the inflammatory state these 
mechanisms can become overwhelmed leading to oxidative/nitrative stress and 
damage to the basic structural and functional elements of the cells.  Reactive 
oxygen and nitrogen species include superoxide ions, hydrogen peroxide, nitric 
oxide and peroxynitrite, all of which are produced as part of the inflammatory 
response.  High levels of NO, peroxynitrite and superoxide have been demonstrated 
in spinal fluid derived from patients with multiple sclerosis (Calabrese et al., 2002) 
and have a clear potential role in the disease processes.  Inflammatory nitric oxide 
synthase (iNOS) mRNA (iNOS is responsible for the production of NO in the CNS) 
has been identified in MS plaques (Bö et al., 1994).  Evidence for reactive oxygen 
species involvement comes from both direct and indirect observations - high levels 
of ROS have been identified in macrophages and microglial cells in mice with EAE 
(Ruuls et al., 1995), with evidence of lipid peroxidation in post-mortem human 
tissue (Newcombe et al., 1994) - thought to play a crucial role in early plaque 
development.  Human MSCs have been demonstrated to possess a number of 
antioxidant properties which help protect against free-radical induced injury 
including secretion of anti-oxidant molecules, specifically superoxide dismutase 3 
(SOD3), with protection of cultured murine cerebellar neurones demonstrated in 
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vitro (Kemp et al., 2010).  MSCs have also been shown to reduce expression of iNOS 
in microglia, further enhancing antioxidant effects (Kim et al., 2009). 
 
Trophic support 
Bone marrow-derived cells have been known for some time to secrete a plethora 
of cytokines including hepatocyte and nerve growth factors and brain-derived and 
glial cell line-derived neurotrophic factors, important in the growth, development 
and maintenance of the human CNS (Crigler et al., 2006).  Human MSCs in coculture 
with mouse neonatal brain cortex express neurotrophin low-affinity (p75) and high-
affinity (trkC) receptors and secrete nerve growth factor and neurotrophin-3 (Pisati 
et al., 2007), clearly demonstrating the functional ability to provide trophic support 
in the CNS environment, specifically those relevant to oligodendrocytes.  Evidence 
for neuroprotective activity beyond immunosuppression comes from studies 
demonstrating therapeutic benefit of MSCs in non-inflammatory CNS pathology 
(Chen et al., 2001).  Our group have previously demonstrated that brain-derived 
neurotrophic factor is secreted by MSCs and ameliorates cell injury in cultured 
rodent cortical neurons via activation of AKT pathways with a central role of the 
phosphatidylinositol 3-kinase and MAPK pathways (Wilkins et al., 2009).  It has also 
been demonstrated that MSCs secrete additional neurotrophic factors when 
exposed to medium conditioned by rodent brain that had undergone experimental 
traumatic injury (Chen et al., 2002).  Modulation of secreted proteins including 
cytokines and neurotrophic factors are thought to enable redirection of  cells from 
apoptotic to survival pathways (Kaplan and Miller, 2000) and is likely to represent 
a key therapeutic activity of MSCs. 
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Interaction with resident stem cells 
The unselected bone marrow-derived mononuclear cell fraction (Sasaki et al., 2001) 
and isolated stromal cells (Akiyama et al., 2002) have been shown to enhance 
remyelination and repair following intravenous administration in non-immune 
rodent models of demyelination.  The mechanism of action in these and other 
examples remains obscure.  In both studies the cells were genetically labelled and 
observed to directly myelinate axons in the damaged spinal cord.  However, 
consensus now suggests that direct replacement is likely to be a rare event 
(Freedman et al., 2010) and consequently interaction with resident stem cells is 
more likely to be of greater therapeutic value.  Evidence for interaction with 
resident stem cells comes from research showing that human MSCs could 
significantly increase proliferation of endogenous neural stem cells expressing the 
stem cell marker Sox2 (Munoz et al., 2005), and the increase in oligodendrocyte 
lineage cells in lesions following injection of human MSCs into mice with EAE with 
evidence that this may be a result of MSC-induced changes in neural cell fate (Bai 
et al., 2009).   Bai and colleagues later identified hepataocyte growth factor (HGF) 
as a key mediator of functional benefit in the administration of MSCs in mouse 
MOG35–55-induced experimental autoimmune encephalomyelitis.  Support for a 
role for paracrine interaction with resident stem cells was achieved with the 
demonstration that remyelination in lysolecithin-induced rat dorsal spinal cord 






Translational studies of human bone marrow-derived cells in MS 
 
Despite the developing consensus regarding the inability of bone marrow cells to 
effect direct cellular replacement, paracrine reparative activities, neuro-protection, 
anti-oxidant and immune effects, and interactions with resident neural stem cells 
are considered to represent valuable potential therapeutic effects of bone marrow-
derived cells in neurodegenerative disease.  The age of translation of the science to 
the clinic has begun and several phase I and II studies have been published (Connick 
et al., 2012; Rice et al., 2010; Yamout et al., 2010).  These studies were not designed 
to detect treatment effects but secondary outcomes did suggest several beneficial 
effects and phase II randomised and controlled studies are underway.   
 
Much work has been done within the field of neuroscience to elucidate the 
properties of bone marrow-derived stem cells given the early evidence of migration 
into areas of CNS disease or damage (Kørbling and Estrov, 2003).  Multipotent 
mesenchymal stromal cells (MSC) have been extensively studied, due in part to 
their ease of isolation and culture, and has displayed pathophysiological effects that 
are theoretically beneficial in MS, as discussed above.  MSCs have consequently 
been adopted as the sole cell to be used by some groups interested in cell therapy 
for neurological disease.  A second, simpler, less expensive approach is to use the 
whole of the bone marrow mononuclear fraction, containing all of the many stem 
cell sub-populations present in the bone marrow.  This approach exploits any 
properties/cell-cell interactions that these additional cell types possess/participate 
in and will also include those cells responsible for the neural integration and 
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transdifferentiation identified in sex-mismatched donor recipients (Mezey et al., 
2003).  Our  group published in 2010 a phase 1 translational study using systemically 
administered autologous whole bone marrow (Rice et al., 2010).  Although 
primarily powered to analyse safety, a beneficial effect in progressive MS was 
suggested by neurophysiological outcome measures and a phase II study is now 
under way.  Although much is now known about the biology of the MSC sub-
population, the use of whole bone marrow inevitably raises questions about the 
biological effects of cells other than MSCs that are introduced into the systemic 
circulation during whole bone marrow mononuclear fraction transfer, as well as 
their eventual fate.  
 
 
Additional cells within the bone marrow niche 
 
As discussed above, the make-up of the non-haematopoietic stem cell component 
of bone marrow continues to be the subject of much debate and attempts at 
classification are complicated by the wide heterogeneity and dynamic nature of the 
cell populations.  Even within the HSC compartment, new cell subsets continue to 
be identified and characterised.  One of these, CD133+ HSCs, are one of the most 
promising candidates for a potential role in neural protection.  CD133 or prominin-
1 was the first member of the prominin family of pentaspan membrane proteins to 
be identified (Miraglia et al., 1997; Weigmann et al., 1997; Yin et al., 1997).  It was 
recognised in this work to be a marker of primitive CD34+ haematopoietic stem cells 
capable of long-term repopulation in xenografted animals, and subsequently to 
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have high clonogenic potential (de Wynter et al., 1998) and significant regenerative 
capacity (Torrente et al., 2004).  Differentiation so far achieved in-vitro by various 
groups includes cells of both mesodermal (Bonanno et al., 2007) and ectodermal 
(Bussolati et al., 2005) lineage.  CD133+ cells isolated from human neural tissue 
were demonstrated to engraft, proliferate, migrate and differentiate in the brains 
of non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice 
(Uchida et al., 2000).  CD133+ cells isolated from the bone marrow compartment 
have been demonstrated to provide protection to neural progenitor cells in the 
context of growth factor/nutrient withdrawal - CD133+ cell-conditioned media 
ameliorated cortical infarct volume in an ischaemic model of neural injury in mice 
(Bakondi et al., 2009).  Further work by this group identified stromal-derived factor 
1 alpha (SDF-1) as a key mediator of neuroprotective activity (Bakondi et al., 2011).   
CD133 is also expressed on endothelial progenitor cells which play a key role in 
angiogenesis both in wound healing and tumour formation (Ribatti, 2004).  The 
early demonstration that cord-derived CD133+ cells can undergo differentiation 
into endothelial and cardiomyocytes in-vitro (Bonanno et al., 2007) has led to 
extensive interest in its potential relevance to cardiac disease, particularly 
myocardial infarction (Acosta et al., 2013). 
  
Other cell markers of promising significance include Stro-1, a marker of early 
stromal cell precursors with enhanced proliferative capacity (Simmons and Torok-
Storb, 1991), and CD271 low affinity nerve growth factor receptor.  CD271 or p75 
neurotrophin receptor is a member of the tumour necrosis factor superfamily and 
has been identified as a marker of primitive mesenchymal cells with greater 
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clonogenic and differentiative capacity than MSCs isolated by plastic adherence 
(Quirici et al., 2002).  Bone marrow-derived CD271+ cells have also been shown to 
possess neuroprotective properties, again within the context of growth factor and 
nutrient withdrawal (Bakondi et al., 2009), and immunosuppressive properties, 
clearly of potential relevance in the context of MS (Kuçi et al., 2010). 
 
 
Assessing the impact of therapies for progressive disability 
 
History of disease measures in MS; 
One of the main hurdles facing any therapeutic trial aiming to reduce the 
progression of disability in MS is that of measuring and assessing disability.  Current 
disability outcome measures have significant problems including insufficient 
sensitivity and reproducibility, inadequate validation and lack of patient subjective 
components.  Despite these problems, a lack of clear alternatives has led to 
widespread use in therapeutic studies. 
 
It was recognised early in the therapeutic age of MS that further development of 
disability measures was necessary.  In 1995 the National MS Society of the USA 
convened an international meeting specifically to look at outcome measures in 
MS clinical trials, concluding that the Expanded Disability Status Scale (EDSS – 
discussed in more detail below) was neither responsive nor sensitive enough and 
appointed task forces to look at specific areas for development in more detail 
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(Whitaker et al., 1995).  Despite no little endeavour over the subsequent 20 years, 





The Expanded Disability Status Scale; 
The first attempts to systematise objective clinical rating systems for Neurological 
impairment in MS appeared in the middle of the 20th century and were quickly 
developed and refined.  In common with many diseases, the emergence of 
potential therapeutics drove the need for an accurate way of measuring the 
disease.  John Kurtzke worked on one such study (of isoniazid in MS) and through 
his work developed the Disability Status Scale (DSS) (KURTZKE, 1961), later refined 
to the Expanded Disability Status Scale (EDSS) (Kurtzke, 1983), still the ‘gold 
standard’ clinical parameter to this day.  The EDSS is a 10-point ordinal scale 
containing 20 different levels of disability ranging from 0 (normal neurological 
examination) to 10 (death due to MS).  The score is based on a synthesis of 
neurological examination findings, ambulation capacity (including requirement of 
unilateral, bilateral or wheeled aid) and level of independence in undertaking 
activities of daily living.  The scale encompasses a wide range of neurological 
functions that are relevant to MS including bowel, bladder and cerebral (fatigue, 




Although rightly recognised for its remarkable contribution to the study and 
treatment of MS, the EDSS has widely acknowledged shortcomings (Hobart et al., 
2000).  The original DSS was criticised for being insufficiently sensitive and 
unresponsive to clinical change, perceived shortcomings that were addressed in the 
design of the more detailed EDSS; whilst this improved sensitivity to small changes 
in Neurological function, it came at the expense of reliability and reproducibility.  
Further concerns arise from the fact that the scale is heavily weighted towards 
ambulation and the integrity of the corticospinal motor tracts, and pays little 
attention to cognitive function.  The EDSS is non-linear; the implication of a 1.0 
score change has vastly different meaning depending on the patient’s position on 
the scale, and progression is partly therefore a function of baseline score 
(Weinshenker et al., 1991), limiting potential statistical interpretation and 
compromising function in therapeutic studies.  Administration of the EDSS brings 
further concerns; it is largely reliant (at least within the lower reaches of the scale) 
on the neurological examination which is inherently subjective, administration is 
complex and time-consuming and scoring somewhat ambiguous with poor intra- 
and inter-rater reproducibility  a somewhat predictable consequence (Amato et al., 
1988).  This variability in the EDSS is particularly troublesome in control cohorts 
where it undermines the ability to detect treatment effects (thus far prevention of 
disease progression) in therapeutic studies - Ebers and colleagues used data from 
the placebo arms of 31 clinical trials and found that disability progression was no 
more likely in this group than improvement, concluding that existing definitions of 
disease progression reflect, among other things, measurement error (Ebers et al., 
2008).  They wrote that surrogates of unremitting disability (utilising the EDSS) in 
58 
 
RRMS ‘cannot be validated’, effectively questioning its role in future therapeutic 
studies. 
 
Despite these well-recognised concerns the EDSS continues to be used as a primary 
outcome measure in pivotal trials of therapeutic agents.  Its primary advantage is 
its established acceptance to regulators and extensive historical use enabling 
comparison between temporally-dispersed cohorts.  Several improvements and 
modifications have been enabled or recommended by the International Advisory 
Committee on Clinical Trials in Multiple Sclerosis to help improve reliability, 
reproducibility and ease of administration (Cohen et al., 2012b). 
 
The Multiple Sclerosis Functional Composite; 
In 1999 a task force instructed by the National Multiple Sclerosis Society's  (NMSS) 
Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis reported 
on the development of a clinical measurement tool designed to reconcile some of 
the shortcomings of the EDSS and other clinical rating scales (Cutter et al., 1999).  
The Multiple Sclerosis Functional Composite (MSFC) comprises of 3 tests designed 
to quantify upper limb function, lower limb function/mobility and cognitive 
function with the 9-hole peg test, a timed 25 feet walk and the paced serial addition 
test.  Each component is normalised by conversion to a z-score measured either 
against a reference control population or the performance of the study population 
at baseline.  Averaging of these 3 components produces a quantitative score on a 
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continuous scale which is much more amenable to statistical analysis and 
interpretation.  Administration of the test takes just 15-20 minutes, depending 
largely on the patient and speed of task completion, and it can be done by a trained 
technician rather than qualified medical (and ideally Neurological) personnel.  
  
Despite the demonstration of correlation with many parameters of MS including 
clinical (Rudick et al., 2009), imaging (Kalkers et al., 2001) and patient-reported 
outcomes (Miller et al., 2000), the MSFC has not been acceptable to regulators as a 
primary endpoint in therapeutic studies.  This is primarily because the composite 
score is abstract, dimensionless and infrequently encountered by physicians, 
limiting clinical interpretation.  Another concern is that using internal baseline data 
to generate z-scores (as opposed to the reference MS population used by the NMSS 
task force in designing the MSFC scoring manual), limits capacity for meta-analysis 
of trial results. 
 
Other methods of quantifying the disease impact of MS currently being explored 
include composite endpoints such as disease activity free status (clinical and 
radiological), global measures of activities of daily living (Rankin scale, Barthel 
index), patient reported outcomes and other novel techniques such as kinematic 





Magnetic Resonance Imaging 
 
Early use of MR imaging in MS revealed the extraordinary ability of the technology 
to visualise some of the core pathological features of the condition in-vivo (Young 
et al., 1981).  The identification and quantification of subclinical disease activity 
clearly had significant implications for diagnosis, becoming a key component of 
diagnostic criteria, as well as prognosis both over the immediate and longer term 
(Fisniku et al., 2008).  Alongside clinically confirmed relapses, imaging parameters 
were widely adopted as surrogate markers used to demonstrate 
immunosuppressive effects of novel therapeutic agents in ‘proof of concept’ 
studies.  These consisted of primarily lesion-based metrics including T2 lesion load 
and activity, and GAD-enhanced T1 lesion number and volume, both widely 
employed in phase I and II clinical trials, a crucial step in bringing today’s 
therapeutics into clinical use (Barkhof et al., 2012). 
 
Biomarkers are an attractive alternative to clinical parameters if they are 
quantitative, reproducible and sensitive to small subclinical changes in disease 
status.  MRI has clearly been a front-runner in this domain for some time; through 
revelation of the effective suppression of immune activity it has been validated as 
a trial-level surrogate endpoint for relapse (the clinical correlate of a focus of new 
inflammatory activity in the CNS) in RRMS (Sormani et al., 2009).  The contribution 
of changes in lesional MRI parameters to variations in disability is however more of 
a contentious issue; studies have drawn conclusions ranging from a significant to 
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little/no contributory effect.  Ebers and colleagues used clinical data from 31 trial 
placebo arms to model the relationship of changes in MRI T2 lesion load to both in-
trial relapses and disability accumulation (as measured using the EDSS) (Daumer et 
al., 2009).  In the RRMS cohort inclusion of Gadolinium-enhancing lesions in 
multivariate models made no independent contribution to relapse occurrence and 
T2 lesion load made no independent contribution to predicting disability.  In the 
SPMS patients included in the analysis, T2 lesion load accounted for less than 5% of 
variance in disability at the conclusion of the trials.  This is contradicted by work by 
Sormani and colleagues which reports that at a study population level, MRI activity 
correlates with relapses, and both MRI activity and relapses correlate with end-of-
trial disability (Sormani et al., 2011a).  Furthermore, in contemporaneously 
published work the same group reported that a combination of MRI metrics (T2 
lesion frequency) and relapse account for up to 100% of the treatment effect on 
worsening of EDSS at 2 years (Sormani et al., 2011b).  Although detailed critique has 
been made of both findings, particularly that of the positive effect (Wolinsky and 
Beck, 2011), it is the authors opinion that the emerging evidence of a 
neurodegenerative component that underlies disability accumulation (and 
effectively progresses independently of neuroinflammation) provides an altogether 
more convincing rationale. 
 
The perceived lack of correlation between inflammation in the substrate of the 
brain and accumulated disability has led to a broad search for alternative 
biomarkers that seek to quantify the neurodegenerative element of the condition 
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and allow prediction of disability accumulation.  In the context of imaging, these 
have included ‘conventional’ MRI features such as T1 hypointense lesions (or 
persistent black holes), global or component brain atrophy and spinal cord atrophy 
(as a surrogate for axonal loss) as well as novel sequences and parameters including 
magnetisation transfer and diffusion tensor imaging.  Composite MRI endpoints 
have been utilised (Wolinsky et al., 2000) but are susceptible to similar criticisms 
that are made of the dimensionless MSFC, particularly as a trial primary end-point.  
Other surrogates gaining clinical traction include neurophysiological parameters, 
serological biomarkers, optical coherence tomography and kinematics. 
 
In seeking to measure the degenerative component of MS, it would seem intuitive 
to perform pilot work in the progressive forms of the condition and specifically the 
primary progressive cohort.  The heterogeneity of the condition of MS remains to 
be fully resolved.  Evidence to suggest a unifying underlying process particularly in 
the context of the progressive phases of the condition has previously been 
discussed.  Compared with secondary progression, primary progressive disease is 
(largely) unencumbered by superimposed inflammatory activity making 
interpretation and analysis of its measurement more robust.  To some it is the ideal 






Neurophysiological surrogates of disease  
 
The use of evoked potentials to interrogate the functional integrity of the human 
CNS was first explored by Dawson in the middle of the twentieth century (Dawson, 
1947) and first applied to MS in the 1960’s (Baker et al., 1968; Namerow, 1968a, b).  
Evoked potentials in which sensory nerve fibres are stimulated and the 
corresponding electrical activity or potential is recorded in the CNS, were initially 
widely used in the identification of clinically silent disease activity, aiding diagnosis 
of the condition.  The first to be explored in the context of MS was the visual-evoked 
potential (VEPs) (Halliday et al., 1972), followed by somatosensory (SSEPs) (Small et 
al., 1978), brainstem auditory (BSAEPs) (Robinson and Rudge, 1977) and electrical 
(Cowan et al., 1984) and then magnetic (Hess et al., 1986) stimulation-induced  
motor evoked potentials (MEPs). 
 
Pattern reversal visual evoked potentials revealed an increase in latency in 90% of 
clinically-confirmed cases of MS (Halliday et al., 1972) and quickly entered clinical 
use (Halliday et al., 1973).  The ability to demonstrate involvement of asymptomatic 
pathways had clear implications for the ability to grade the risk of development of 
disseminated MS, and was widely used in early diagnostic criteria.  According to a 
consensus report produced in 2000 by the quality standards subcommittee of the 
American Academy of Neurology, visual evoked potentials were felt to be more 
valuable supporting evidence for the development of definite MS than sensory EPs, 
whilst there was insufficient evidence for the use of BSAEPs in this context 
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(Gronseth and Ashman, 2000).  MRI, with its greater sensitivity to subclinical 
disease activity in all modalities except visual (Davies et al., 1998), has superseded 
EPs in a diagnostic capacity and this is reflected in modern diagnostic algorithms.  
The only EP to retain utility in the 2001 McDonald diagnostic criteria was the VEP 
and then only in the context of progressive disease from onset (McDonald et al., 
2001).  When these criteria were updated in 2005, EPs disappeared altogether from 
the algorithms (Polman et al., 2011; Polman et al., 2005). 
 
Although their use in the diagnosis of MS is now redundant, evoked potentials have 
over the last 1-2 decades been gaining attention as a method to quantify the 
functional integrity of white matter tracts and by extension potentially perform as 
a surrogate for disability.  Combining the different EPs to produce a multi-modal or 
global score has repeatedly shown correlation with clinical disability in both cross-
sectional (Invernizzi et al., 2011; Leocani et al., 2006) and longitudinal analysis (Fuhr 
et al., 2001; Jung et al., 2008; Schlaeger et al., 2012b), and demonstrated an ability 
to predict the extent of progression of disability (Schlaeger et al., 2012a; Schlaeger 
et al., 2014b), all in mixed populations.  Subsequent to initiation of the study 
reported in this thesis, a study looking at correlation of EPs with disability within a 
PPMS cohort has been published (Schlaeger et al., 2014a) though the cohort was 
small (just 22 patients with 6 failing to complete the study).  Direct comparison with 




Studies combining evoked potentials from different modalities have done so using 
a variety of techniques with none gaining pre-eminence.  The measuring of 
amplitude of EPs is compromised by central amplification within the CNS, 
restricting assessment of axonal dysfunction or loss.  Quantitative aspects of the 
latency of the EP are therefore integral and can be used alone (either 
transforming to an ordinal or continuous scale) or in conjunction with qualitative 
aspects of the recording.  Ordinal scales have the advantage of smoothing the 
inherent fluctuation of neuronal function and convincingly accommodating absent 
potentials.  The last point is a particular problem when using a raw EP or z-
transformed (in which the raw score is converted to the number of standard 
deviations that it lies from the mean) latency.  Methods to account for absent 
potentials include the use of quotients or average scores for summation of 
modalities (Schlaeger et al., 2014a), or direct replacement with the cohort 
maximum value (Fuhr et al., 2001).  The correlations achieved by the different 
methods are largely comparable with a maximum reported Spearman correlation 
coefficient of 0.75 (Fuhr et al., 2001) achieved using continuous scale raw latency 
transformation of the MEP and VEP only.   
 
 
Novel MRI parameters 
  
In the context of active relapsing-remitting disease (although clearly related to 
inflammation) lesional metrics such as T1 persistent black holes (representative of 
tissue rarefaction following axonal injury) and magnetisation transfer ratio (a 
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measure of the transfer of nuclear spin polarisation which is elevated in white 
matter lesions (Filippi et al., 2013)) show promise for sensitivity to change in 
disability status both over time and in response to a treatment effect (Giacomini 
and Arnold, 2008).  The reduction of inflammatory activity by powerful new 
therapeutics will inevitably compromise the ability of lesional metrics to reveal in-
study neuroprotection and/or repair.   
 
Given current concepts and understanding of the pathophysiology of MS, it seems 
intuitive that imaging modalities and sequences that seek to correlate with axonal 
dysfunction/loss are more likely to be able to capture the neurodegenerative 
element of the condition that underlies disability accrual, and consequently any 
neuroprotective effects (and beyond that tissue repair) of novel therapeutic agents.  
The most obvious of these is atrophy of CNS tissue; brain atrophy has been shown 
to correlate well with disability measures (Simon, 2006) and segmentation of brain 
volumes enables a degree of circumvention of some of the more obvious criticisms 
of this technique – namely susceptibility to confounds such as inflammatory tissue 
swelling, and increase in glial cell content.  Studies have shown that perhaps 
counter-intuitively, grey matter atrophy is greater than that seen in white matter, 
at least early in the disease course (Tiberio et al., 2005).  Atrophy of the spinal cord 
has shown even greater correlation with levels of disability (r = 0.7) in a mixed 
cohort of patients with MS (Losseff et al., 1996), thought to reflect the eloquence 




Advanced sequence imaging abnormalities of both white and grey matter that 
appears normal on standard sequences have provided important insights into the 
pathology of MS (Bakshi et al., 2008), and underscored a paradigm shift away from 
the traditional view of a ‘disease of lesions’ (Rice et al., 2013).  Modalities used to 
assess normal appearing tissue include magnetisation transfer ratio (MTR), 
diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (MRS).   
 MTR reflects the magnetisation exchange between protons in tissues (either 
free or bound to macromolecules) and is decreased in tissue injury.  Post-
mortem studies have demonstrated clear correlation with both the degree 
of demyelination and percentage of axonal loss (van Waesberghe et al., 
1999) and this translates to correlation with neurological physical disability 
(Hayton et al., 2009).  Within a pure PPMS cohort normal appearing grey 
matter MTR has been shown to correlate with the requirement for a walking 
aid (Rovaris et al., 2008).   
 DTI similarly correlates with axonal loss and demyelination (Mottershead et 
al., 2003).  The technique can be used to generate measures of the direction 
(fractional anisotropy) and magnitude (mean diffusivity) of the Brownian 
motion of water molecules within tissues.  Identification of white matter 
tracts can be achieved using the sequences, further enhancing the 
functional relevance of the parameters.  Mean diffusivity (MD) shows an 
increase and fractional anisotropy (FA) a decrease in both normal appearing 
white and grey matter in patients with MS (Rovaris et al., 2005) and 
corticospinal tract measures of both correlate with disability measures 
(Tovar-Moll et al., 2015).   
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 Proton MR spectroscopy is able to measure N-acetyl-aspartate (NAA) levels, 
a correlate of neuroaxonal integrity.  Studies in MS have revealed a 
reduction in levels in lesions and in normal appearing white matter that 
correlates with levels of disability (Sajja et al., 2009) and has underlined the 
hypothesis that progressive loss of axons is a key factor in the irreversible 
accumulation of disability in MS (Rocca et al., 2012).  In PPMS total NAA 
levels in cortical grey matter have been shown to better correlate with EDSS 





The hypothesis underlying this work is that bone marrow-resident stem cell 
populations have the capacity to limit injury and enhance repair within the CNS in 
human demyelinating disease, and that both post-mortem brain tissue and ante-
mortem blood samples will yield evidence of mobilisation of these cells within the 
normal pathophysiology of the disease.   
 
With respect to the quantification of disease status I hypothesise that 
neurophysiological parameters will provide better correlation with clinical 
measures of disease status and further support their use in the design of 






The attempt at identification of cells of bone marrow origin was to be carried out 
in post-mortem brain samples obtained from patients with MS and in blood 
samples collected from patients attending the regional MS centre for clinical 
review; 
 Identification of haematopoietic and mesenchymal cells within MS brain 
tissue using immuno-histochemical and -fluorescent techniques 
 Identification of the same cell populations in blood samples using flow 
cytometric techniques 
Interrogation of neurophysiological parameters as surrogates of disease status in 
PPMS would be carried out on data collected in an ongoing clinical project set up 
prior to the start of this thesis.  A comparison with radiological parameters was 
planned and would entail recruitment of patients from the same cohort into an 















Cells of bone marrow origin have for some time been hypothesised to contribute 
to spontaneous tissue repair in a range of diseases and a variety of tissues, including 
the central nervous system (Kørbling and Estrov, 2003).  Initially, 
transdifferentiation to replace damaged cells was considered the principal 
mechanism of benefit.  This was supported by studies of post-mortem brain tissue 
from sex-mismatched bone marrow transplants in which astrocytes and neurons of 
the donor gender constituted 1% of hippocampal neurons and astrocytes (Cogle et 
al., 2004).   
 
In relation to disease of the brain however, there is now significant and widespread 
doubt concerning the ability of bone marrow cells directly to generate both 
neurones and myelinating oligodendrocytes.  Whilst a certain amount of evidence 
exists for neural transdifferentiation of both mouse and human marrow-derived 
cells (Cogle et al., 2004; Eglitis and Mezey, 1997), paracrine reparative activities of 
bone marrow cells, including neuroprotection (Kemp et al., 2010), immune effects 
(Uccelli et al., 2007), and interactions with resident neural stem cells (Munoz et al., 
2005) have been demonstrated and are thought to represent valuable potential 
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therapeutic effects in the context of neurodegenerative disease.  Whatever the 
mechanism of benefit, certain bone marrow-derived cells clearly enter the 
peripheral circulation and then actively migrate into the damaged CNS (Kørbling 
and Estrov, 2003) - the ability of marrow-derived cells to infiltrate the CNS has 
repeatedly been demonstrated in both inflammatory and non-inflammatory 
conditions (Akiyama et al., 2002; Devine et al., 2003).  In EAE, the murine model of 
Multiple Sclerosis (MS), human MSCs have demonstrated the property of disease 
abrogation in association with evidence of cellular infiltration of the CNS (Gordon 
et al., 2008), including specifically to white matter lesions (Gordon et al., 2008; 
Gordon et al., 2010).  Mobilisation of bone marrow-derived cells, and specifically 
MSCs, is currently being explored as a potential therapy for MS.  Little however, is 
known about their activity and fate in-man (as opposed to animal models).  Further 
knowledge in this area would undoubtedly help in refining bone marrow transfer 
therapies for the disease. 
 
No single marker exists that can reliably be used to identify MSCs though minimum 
criteria for their identification including patterns of surface markers (on a 
population basis) have been published, forming an accepted research standard 
(Dominici et al., 2006).  CD271 or p75 neurotrophin receptor is a member of the 
tumour necrosis factor superfamily.  It has been identified as a marker of primitive 
mesenchymal cells with greater clonogenic and differentiative capacity than MSCs 
isolated by plastic adherence (Quirici et al., 2002).  Bone marrow-derived CD271-
positive cells have been shown to possess neuroprotective properties within the 
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context of growth factor and nutrient withdrawal (Bakondi et al., 2009), and 
immunosuppressive properties (Kuçi et al., 2010).  As well as expression by MSCs, 
CD271 or low-affinity nerve growth factor receptor is expressed by neuronal cells 
where it is thought to play a role in promoting survival and differentiation (Lv et al., 
2014).  It has not been identified in white matter, the location of classical 
demyelinating lesions in MS and therefore is a good candidate for identification of 
MSCs in brain tissue. 
 
We aimed to establish whether bone marrow-derived cells incorporate into the 
multiple sclerosis lesion during the natural course of the disease and how they 
might integrate to facilitate endogenous repair.   
 
 
Materials and Methods 
 
Tissue for the study was provided by the UK Multiple Sclerosis Tissue Bank at 
Imperial College, London.  Paraffin-embedded tissue from 14 neuropathologically 











MS phenotype Disease duration 
(years) 
Cause of death Lesion type/Neuropathology 
1 Control 93 F n/a n/a Bronchopneumomia, 
cerebrovascular accident 
Age-related changes only 
2 Control 82 M n/a n/a Unknown Mild Alzheimer-type changes and features of 
possible ischaemia of the internal capsule 
3 Control 71 M n/a n/a Abdominal and retroperitoneal 
haemorrhage, ruptured spleen 
Age-related changes and focal leptomeningeal 
infiltration of leukaemic cells 
4 Control 88 M n/a n/a Prostate cancer, bone metastases Age-related changes, no metastatic disease 
5 Control 84 F n/a n/a Pancreatic cancer Age-related and mild Alzheimer-type changes, no 
metastatic deposits 
6 Control 82 M n/a n/a Metastatic lung and liver cancer Micro-metastasis in anterior caudate only 








MS phenotype Disease duration 
(years) 
Cause of death Lesion type/Neuropathology 
7 MS 77 M SPMS 39 Bronchopenumonia Active 
8 MS 56 F SPMS 34 Septicaemia due to UTI Active 
9 MS 51 M PPMS 2 Bronchopneumonia Active 
10 MS 35 F SPMS 5 MS Active 
11 MS 45 F SPMS 16 MS Active 
12 MS 64 M SPMS 26 Bronchopneumonia, MS Chronic active 
13 MS 63 F SPMS 26 UTI, MS Chronic active 
14 MS 55 M SPMS 20 MS Chronic active 
15 MS 74 M SPMS 37 Bronchopneumonia, MS Chronic active 
16 MS 44 F SPMS 19 Urinary tract infection, MS Chronic inactive 
17 MS 53 M SPMS 33 Septicaemia due to UTI, MS Chronic active, chronic inactive 
18 MS 83 F SPMS 40 Septicaemia, bronchopneumonia, MS Chronic inactive 
19 MS 59 M SPMS 39 Multiple sclerosis Chronic inactive 
20 MS 72 M SPMS 43 Bronchopneumonia, MS Chronic inactive 




Lesions were first characterised using solochrome cyanine, myelin basic protein 
(MBP) and HLA DP/DQ/DR - 3,3’-diaminobenzidine (DAB) staining.  For the purpose 
of solochrome cyanine staining, sections were first dewaxed and hydrated before 
staining in solochrome cyanine solution for 10 minutes, differentiation in 10% Iron 
Alum (aqueous) for 5 minutes and counterstaining with Kernechtrot solution for 15 
minutes, all at room temperature with interspersed washes to intensify staining.  
Sections were then dehydrated and mounted.  Sections were stained with 
antibodies to MBP (1:3200; Serotec, Oxford, UK) and HLA DP/DQ/DR (1/800; Dako, 
Denmark).  Controls (control sections and MS sections without primary antibody 
incubation) were included in each run.  Sections were first dewaxed and hydrated, 
and then immersed in 3% hydrogen peroxide in methanol for 30 min to block 
endogenous peroxidase activity.  Antigen retrieval was performed with repeated 
heating in sodium citrate buffer (0.01 M, pH 6.0, 5 min) or 
Ethylenediaminetetraacetic acid (EDTA) buffer (1 mM, pH 8, 10 min) as appropriate 
and rinsed in phosphate-buffered saline (PBS).  Non-specific binding was blocked 
by 20-minute immersion in Vectastain blocking serum (Vector Laboratories, 
Peterborough, UK).  Primary antibodies were diluted in 3% BSA/0.1% Azide and 
sections incubated for 18 hours at 4oC.  The sections were then rinsed in PBS before 
incubation for 20 min with secondary antibody (Vectastain Biotinylated Universal 
antibody) and 20 min with Vectalite ABC complex (Vector Laboratories, 
Peterborough, UK).  DAB and 0.01% H2O2 was then added to the sections for 10 
minutes before washing and immersing in copper sulphate DAB enhancer (4 min).  
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Cell nuclei were counterstained with hematoxylin and the sections dehydrated, 
cleared and mounted.   
 
Immuno-fluorescent labelling of paraffin-embedded sections; 
Sections were dewaxed, hydrated and washed as above.  Sections were incubated 
for 1 hour in 5 mM copper sulphate and 50 mM ammonium acetate at room 
temperature to block auto fluorescence.  Antigen retrieval was then performed by 
repeated heating in sodium citrate buffer (0.01 M, pH 6.0, 5 min).  Sections were 
incubated for 1 hour at room temperature in 10% normal goat serum (NGS) diluted 
in PBS containing 0.1% triton to block non-specific antibody binding and then in the 
primary antibodies diluted in 10% NGS/PBS for 18 hours at 4oC.  Cell 
characterisation using double immunofluorescence was performed using a number 
of cell markers in varying combinations.  These consisted of antibodies to MBP and 
HLA DP/DQ/DR (1:400) as above, Iba-1 (1:250), NG2 (1:500), GFAP (1:5000), CD3 
(1:250), CD68 (1:800), CD34 (1:250), CD45 (1:100), CD73 (1:250), CD90 (1: ), CD105 
(1:200), CD271 (1:400) (all Abcam, Cambridge, UK) and Stro-1 (1:200; Millipore, 
Massachusetts, USA).  Sections were then washed in PBS and incubated for 30 min 
in the dark with the appropriate species-specific secondary Alexa Fluor 488/555 
antibodies (1:500; Invitrogen, Paisley, UK).  After a further wash sections were 
washed in PBS and mounted in Vectashield medium containing the nuclear dye 4′6′-
diamidino-2-phenylindole (DAPI).  Imaging was performed using an inverted Leica 
CTR 6000 fluorescence microscope and merged with Leica Application Suite 
Advanced Fluorescence software. 
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Stro-1/CD271 immunoperoxidase labelling of paraffin-embedded sections; 
Sections were prepared as for MBP and HLA DP/DQ/DR labelling for the purposes 
of lesion characterisation.  Sections were labelled with anti stro-1 (1:800; Millipore, 
Massachusetts, USA) or anti-CD271 antibodies (1:400; Abcam, Cambridge, UK), 
incubated for 18 hours at 4oC.  Antibody was labelled with DAB using the Vectastain 
Universal Kit.  Acquisition of images was performed using an Olympus IX70 
microscope (Olympus, UK) and Image Pro-Plus software (Bethesda, USA).  Cell 
quantification was performed with the aid of Image-J software (NIH, USA). 
 
Statistical analysis; 
Statistical analysis of the data was carried out using a regression model that enabled 
adjustment/correlation for multiple sections taken from the same patient/brain 
(cluster option).  Non parametric bootstrap analysis was used to estimate standard 
errors and 95% confidence intervals to account for potential non-normality of data.  
The statistical analysis was carried out using STATA v12 (StataCorp, TX, USA) and 
graphs generated using GraphPad PRISM 5™ (Graph Pad Software, CA, USA).  Values 










Lesion identification and activity was first established in the paraffin-embedded 
sections.  Areas of demyelination were readily identifiable using solochrome 
cyanine staining and immunolabelling for MBP within the sections derived from 
patients with MS.  No evidence of demyelination was seen in any of the control 
samples.  Sections derived from the patients with MS were immunolabelled with 
antibody to the macrophage/microglial markers HLA-DP/DQ/DR allowing 
classification of demyelinated lesions as active, chronic active or chronic inactive, 
according to levels and distribution of HLA-DP/DQ/DR positive cells.  In active 
lesions microglia are seen throughout the area of demyelination; in chronic active 
lesions there is a rim of activated microglia at the periphery of areas of 
demyelination with cells demonstrating typical thickened ramifications - infrequent 
positive cells are also seen within the body of the lesion; in chronic inactive lesions 
there is sparse distribution of microglia throughout the lesion.  In non-demyelinated 
white matter adjacent to areas of demyelination HLA-DP/DQ/DR positive cells were 
also seen in an evenly distributed but less numerous pattern.  Minimal or no 
positive cells were identified in the white matter in the sections from control 
subjects.  6 cases containing active lesions, 5 containing chronic active and 5 cases 





Figure 2.1; Representative histological sections from a control subject showing 
intact white matter and minimal evidence of infiltration of activated microglia; A, D 
- solochrome cyanine stain (blue) identifies white matter; B, E - DAB-
immunolabelled (brown) Myelin Basic Protein identifies myelinated white and grey 
matter; C, F - DAB-immunolabelled (brown) HLA-DP/DQ/DR identifies activated 
microglia.  Magnified images (D-F) are taken from within the same region of white 
matter identified by red broken box in A-C. Nuclei stain pink (kernechtrot) in A and 
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Figure 2.2; Representative section from patient with MS demonstrating an active 
and chronic active lesion. Sections labelled with solochrome cyanine, MBP and HLA-
DP/DQ/DR are displayed as in Fig 2.1.  Chronic active lesion (outlined with green 
broken line in A) is denuded of myelin and has a rim of activated microglia at the 
periphery of the lesion (identified with HLA-DP/DQ/DR immunolabelling in C).  
Active lesion (outlined with yellow broken line in A) is similarlay denuded of myelin 
but shows diffuse infiltration of activated microglia as seen in C.  Magnified images 
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Identification and characterisation of CD271-positive cells;  
Millipore anti-CD271 antibodies 
Prior to staining of MS brain sections, MSCs cultured by plastic adherence were 
immunolabelled as a positive control.  Initial work was performed using Rabbit anti-
CD271 IgG produced by Millipore.  Cultured MSCs were readily co-labelled with 
anti-CD271 and anti-CD105 antibodies (see fig 2.3a).  The CD271 immunolabels had 
a perinuclear predominance with less marked staining in the cell body.  Anti-CD105 
produced homogenous cytoplasmic staining and the control samples (with no 













Figure 2.3; Cultured MSCs demonstrated co-expression of CD271 and CD105; 
CD271 is expressed in a perinuclear distribution.  CD271 stained red (Alexa-Fluor 
555) and CD105 green (Alexa-Fluor 488); nuclei are blue (DAPI).  B represents 











To determine whether CD271-positive cells were present in brain sections from 
patients affected by MS we screened DAB immunolabelled examples of each of the 
lesion-types (active, chronic-active and chronic-inactive).  Linear structures 
redolent of elongated processes were visible in areas with little MBP staining that 
may have represented denuded axons (fig 2.4c).  In the active lesions and at the 
periphery of chronic-active lesions, cells with small cytoplasms which did not relate 
to areas of MBP staining were visible (fig 2.4d).   
 
Further characterisation of these cells was performed using double 
immunofluorescence.  The cells were negative for a number of markers found on 
cell types known to be prevalent in demyelinated MS lesions including; CD3 (T-
lymphocytes), CD45 (leucocyte common antigen), CD68 (Macrophages), Iba-1 
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(activated Microglia), GFAP (astocytes), MBP (mature oligodendrocytes) and NG2 
(oligodendrocyte precursor cells). 
 
Figure 2.4; Cells staining positive for CD271 were prevalent in areas of active 
inflammation. A HLA-DP/DQ/DR DAB-immunolabelled (brown) section from 
patient with MS and B corresponding section labelled with anti-CD271 antibody.  
C and D are taken from region of interest outlined by broken red line in B.  Scale 










Figure 2.5; Cells staining positive for CD271 did not display colabelling with any of 
a plethora of cell markers.  Immunofluorescent images (B-H) taken from area of 271 
DAB-immunolabelled staining (brown) outlined by red broken line in A.  CD271 is 
labelled with Alexa-Fluor 555 (red) and the co-label marker (B-CD3; C-CD45; D-
CD68; E-Iba-1; F-GFAP; G-MBP; H-NG2) with Alexa-Fluor 488 (green) in all images.  
White arrow heads identify cells that stain positive for CD271 but not for the co-
label.  Where not apparent in the main image, small inserted images demonstrate 
























Abcam anti-CD271 antibodies 
I next labelled laboratory-cultured MSCs with an alternative anti-CD271 antibody 
due to failure of inhibition of staining with Millipore antibodies with an Abcam 
CD271 peptide block.  The MSCs again readily co-labelled with anti-CD271 and anti-
CD105 antibody (Fig 2.4a).  In contrast to the Millipore antibodies, staining with 
anti-CD271 was in a heterogenous cytoplasmic pattern with a slightly lobulated 
matrix-like appearance and without the previously witnessed perinuclear 
preponderance.  CD105 labelling again produced the homogenous cytoplasmic 
pattern of staining and the negative control (incubated with PBS instead of primary 













Figure 2.6; Cultured MSCs demonstrated co-expression of CD271 and CD105; 
CD271 distribution was different to that seen using Millipore antibodies (see Fig 
2.3).  CD271 is stained red (Alexa-Fluor 555) and CD105 green (Alexa-Fluor 488); 








Anti-CD271 DAB-immunolabelling of the different types of MS lesions was then 
performed, revealing positive cells in areas of inflammatory activity (Fig 2.7) – 
namely active lesions and the periphery of chronic active lesions.  Labelling of the 
cells was confirmed using immunofluorescence.  Furthermore the labelling was 
inhibited by the use of a CD271 peptide block (Fig 2.8).  Further cell characterisation 
was performed using double immunofluorescence which demonstrated co-
expression of CD271 and Stro-1 (Fig 2.9).  Stro-1 cellular expression was confirmed 
using DAB-immunolabelling which demonstrated positive cells in correlation with 












Fig 2.7; Cells expressing CD271 were readily identifiable in areas of active 
inflammation. Image shows DAB-immunolabelled (brown) CD271 positive cells; 












Fig 2.8;  A CD271-positive cells are also identified using immunofluorescence and B 
staining is inhibited using CD271 peptide block.  CD271 labelled with Alexa-Fluor 















Figure 2.9; CD271-positive cells found in areas of active inflammation within MS 
lesions are also Stro-1-positive.  A Double immunofluorescence demonstrating co-
labelling of CD271 (red) and Stro-1 (green).  DAB-immunolabelling confirmed the 
















CD271+ cell numbers and proportion within the different types of lesions were next 
quantified.  Regions of interest were identified manually using MBP- and HLA-
DP/DQ/DR labelled adjacent sections.  Cell numbers were counted in a 320μm x 
240μm area (0.0768mm2) area selected at random under low resolution.  Data was 
acquired in triplicate at x20 magnification.  Cluster option modelling was used to 
adjust for multiple sections from the same subject.  Overall the number of cells 
were higher in the areas of active inflammation, whether this was lesion-wide (as 
in active lesions) or in an active periphery (as found in chronic active lesions).  
Within the infiltrating cell cohort in the active lesion a significantly higher 
percentage of CD271-expressing cells was found compared with control samples, 
chronic inactive and chronic active lesions.  We also found a higher proportion of 
CD271+ cells when comparing with normal-appearing white matter from the same 
section in both the active and chronic inactive lesions but not in the chronic active 
lesions.  Finally within the chronic active lesions the presence of CD271+ cells 
mirrored that of activated microglia with a higher proportion found at the active 
rim compared with the lesion as a whole or indeed adjacent NAWM.  The 
proportion seen in areas of active inflammation at the periphery of the lesions was 






Fig 2.10; A Proportion of CD271+ cells is higher in active lesions when compared 
with control sections.  There is also a higher proportion in the chronic inactive 
lesions; B Proportion of CD271+ cells in active, chronic active and chronic inactive 
sections compared with normal-appearing white matter (NAWM) from the same 
tissue samples; C Proportion of CD271+ cells is higher in the active rim of the chronic 
active lesion compared with NAWM though not the lesion as a whole.  There is no 














































































































































Here, we have demonstrated the presence of cells expressing CD271 and Stro-1, 
two markers that are expressed by multipotent mesenchymal stromal cells, within 
areas of active inflammation in brain samples taken from patients with MS.  The 
cells did not express markers seen on a multitude of inflammatory and resident glial 
cells that constitute most previously identified cells within white matter MS lesions.  
Cell numbers are clearly highest in active lesions but were also seen in chronic 
active and even chronic inactive lesions to a greater extent than control brain tissue.  
Furthermore, adjacent to areas of immune activity, in so-called normal-appearing 
white matter (in which myelin is intact), the presence of diffuse activated microglia 
was accompanied by the presence of more of these cells than were seen in control 
subject white matter. 
 
The frequency of lesion-based Stro-1/CD271+ cells identified in this work was higher 
than might have been intuitively predicted but corroborative evidence in the 
literature is lacking - as far as we are aware no group has previously sought to 
identify cells expressing these markers in human post-mortem tissue despite 
several studies identifying MSC migration into the CNS in EAE (Gordon et al., 2008; 
Gordon et al., 2010).  No plausible alternative explanation for the presence of these 
Stro-1/CD271+ cells was identified in this work - co-localisation of various markers 
of resident glial and immune cells was not demonstrated. The changes in cell 
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surface markers and or differentiation of MSCs following introduction in humans is 
unknown.  Whilst the cells did not display markers such as CD90 and CD105, it 
remains a possibility that expression has been downregulated in-vivo. 
 
The precise function of Stro-1 is unknown.  It is a 75kd single pass type I protein that 
has been shown to translocate from the endoplasmic reticulum to the cell 
membrane in response to intracellular calcium depletion (Barkhordarian et al., 
2011).  Its use as a marker for MSCs is well established.  Whilst Stro-1 is also 
expressed on endothelium and has been identified in various organs including but 
not limited to the liver, lung and kidney (Lin et al., 2011; Ning et al., 2011), the cells 
identified in this work were not found in close proximity to vascular structures. 
 
The potential identification of MSCs in the CNS of human subjects with MS would 
be consistent with a wide body of evidence from animal studies.  It is well 
established that bone marrow-derived stem cells are able to migrate and infiltrate 
sites of tissue injury in animal models of neural insult (Chopp and Li, 2002; 
Mahmood et al., 2003; Mahmood et al., 2005) including in inflammatory pathology 
such as EAE (Gordon et al., 2010), the murine model of MS.  Despite the problem 
of lung sequestration of intravenously delivered cellular therapies (Fischer et al., 
2009) MSCs have been identified in the CNS after such delivery (Gerdoni et al., 
2007; Kassis et al., 2008; Zhang et al., 2006) with several authors postulating that 
local infiltration is a prerequisite for neuroprotection (Kassis et al., 2008; Zhang et 
98 
 
al., 2006).  Indeed MSCs were even found to be present in the CNS of mice with EAE 
when administered via the intra-peritoneal route (Gordon et al., 2008). 
 
The neurobiology of this migratory capacity has been extensively studied with the 
identification of multiple chemotactic molecules able to promote MSC infiltration 
of damaged tissue (Honczarenko et al., 2006; Kitaori et al., 2009; Lee et al., 2006; 
Ringe et al., 2007).  These include the growth factors platelet-derived growth factor 
AB (PDGF-AB) and insulin-like growth factor 1 (IGF-1) (Ponte et al., 2007) and 
chemokines including stromal-derived factor 1 (SDF-1) (Ponte et al., 2007; Yu et al., 
2016).  Furthermore preincubation of MSCs with specific inflammatory cytokines 
has been shown to upregulate CXCR4 expression and enhance SDF-1-mediated cell 
migration suggesting a preconditioning function of the systemic inflammatory 
response (Yu et al., 2016). 
 
The relevance of these findings to the use of MSCs as a potential therapy for 
protection and repair in MS is clear.  Whilst our understanding of MS as a diffuse 
brain disease rather than a ‘disease of lesions’ has led to a refocus on the concept 
of remote or systemic effects of these cells, direct infiltration of lesions and brain 
parenchyma more widely would provide a more intuitive explanation for their 
hypothesised benefit.  Indeed many have already suggested that this is a 
prerequisite for effective protection and repair of neurons.  Evidence of this 
occurring in human subjects with MS has not previously been reported.  Given the 
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inherent problems associated with cell marker plasticity, until biological labels that 
are safe in human use are developed the question of MSC infiltration of the brain 
























Bone marrow has traditionally been thought of as containing haematopoietic stem 
cells (HSCs) and stromal ‘support’ cells including multipotent mesenchymal stromal 
cells (MSCs).  Bone marrow-derived cells have been shown to have reparative 
potential in several neurological diseases including multiple sclerosis and clinical 
trials are in progress (Rice et al., 2013). 
 
CD34 is a cell surface marker widely used in clinical bone marrow transplantation 
to identify HSCs capable of repopulating the bone marrow after myeloablative 
therapy.  Release of CD34+ haematopoietic stem cells (HSC) and the CD133+ subset 
(associated with high proliferative (de Wynter et al., 1998) and differentiation 
potential (Torrente et al., 2004)) into the peripheral circulation has recently been 
demonstrated in patients receiving anti-CD49d monoclonal antibody (Natalizumab) 
for the treatment of multiple sclerosis (Bonig et al., 2008; Jing et al., 2010; Zohren 
et al., 2008).  Potential mechanisms of repair and/or remodelling of non-
haematopoietic tissue by haematopoietic stem/progenitor cells have been 
demonstrated (Gordon et al., 2006).  Whether these cells contribute to disease 
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modification and tissue repair in MS is not currently known but suggests that the 
monoclonal antibody may have treatment effects beyond immunosuppression.   
 
No single cell surface marker has been identified that reliably isolates MSCs.  These 
cells are characterised by the presence and absence of expression of multiple cell 
surface markers, adherence to plastic in vitro and potential to differentiate into fat, 
cartilage and bone (Dominici et al., 2006).  Isolation and identification of these rare 
cells in the peripheral circulation has been challenging, usually being achieved in 
the context of administration of granulocyte colony-stimulating factor (G-CSF) 
(Kassis et al., 2006) or isolation of small cell subsets obtained through centrifugation 
of large volumes (up to 500ml) of peripheral blood (Zvaifler et al., 2000). 
 
Flow cytometry is a powerful tool enabling analysis of cell physical and chemical 
properties on an individual cell basis.  Early impedance-based devices used the 
Coulter principle to measure cell/particle size whilst modern fluorescence-based 
devices use specific electromagnetic wave-length excitation and emission to 
identify antibody/molecule-conjugated fluorochromes.  Advances in affinity 
reagent technology, particularly monoclonal antibody development, in parallel with 
technological advances and data analysis techniques have enabled the 
development of multiparameter or polychromatic flow cytometry in which multiple 
cell markers and physical characteristics can be analysed simultaneously.  The 
identification of cell populations through expert manual partitioning or ‘gating’ of 
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cell populations is performed visually using 1 or 2-dimensional plots of repeated 
‘events’ ie the measured parameter of each cell that has been analysed.  The use of 
multidimensional plots enables simultaneous visual analysis of several different cell 
parameters (in this instance, cell surface markers) with clear implications in rare 
event detection.  This technology has not been applied to detection of MSCs in the 
peripheral blood stream.   
 
Detection of the presence of bone marrow-derived stem cells in the peripheral 
circulation would provide evidence for their mobilization, supporting the theory of 
migration from bone to brain, and identifying potential therapeutic mechanisms of 
clinically available drugs.  CD34+ cell mobilization in patients receiving anti-CD49d 
monoclonal antibodies for the treatment of MS has already been established (Bonig 
et al., 2008).  Higher levels of circulating CD34+ cells were accompanied by a lower 
proportion of CD133+ CD34+ cells, though an elevation in their overall numbers.  It 
is possible these cells are contributing to the treatment effect of the drug which 
also has powerful anti-inflammatory functions, impairing trafficking of mature 
lymphocytes.  Circulating levels of these cells in patients treated with other 
pharmacological agents, including alemtuzumab have not yet been quantified, nor 
has work looked at the different subsets of disease phenotypes, or at alternative 
circulating bone marrow-derived stem cell populations.   
 
The ability to identify stem cells at small numbers in the peripheral circulation will 
also have significant benefits for the monitoring of stem cell populations during 
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systemically administered therapies for a wide range of neurological and non-
neurological conditions. 
 
In this work we aimed to determine whether HSCs are mobilised during an acute 
MS relapse or by treatment with disease-modifying drugs (DMDs) other than 
Natalizumab.  We also aimed to develop a novel multichannel flow cytometric 
technique to enable identification of MSCs and to quantify their release under the 
same conditions.   
 
 
Materials and Methods 
 
Identification of Haematopoietic Stem Cells; 
Blood samples were collected from consenting patients and control subjects 
attending a regional MS centre for the purposes of ongoing clinical care.  Relapses 
and MS phenotype were identified by the treating neurologist with identification of 
disease-modifying therapies from participant’s records.  Samples were collected 
from MS patients (n=67) and control subjects (n=6) who did not have MS or other 
neurological illness.  Of the 67 patients with MS, 56 had relapsing-remitting MS, 4 
had primary progressive MS and 7 had secondary progressive MS.  The breakdown 





No DMD 7 5 
Beta-interferon 9 2 
Copaxone 5 0 
Fingolimod 1 0 
Natalizumab 10 3 
Alemtuzumab 6 0 
 
Relapse samples were taken prior to the administration of corticosteroids and 
samples from those receiving Natalizumab or Alemtuzumab prior to infusion.  
Procurement of samples was in accordance with Research Ethics Committee 
approval following the acquisition of informed consent.   
 
Blood samples were collected in ethylenediaminetetraacetic acid (EDTA) by MS 
nurse practitioners at the regional MS centre and stored at 4oC.  Samples were 
processed within 72 hours to avoid cell loss or alteration to patterns of cell surface 
marker expression.  50μl of blood was incubated for 15 minutes at 21oC with 10μl 
anti-CD45 (BD Biosci 345808 FITC) and anti-CD34 (BD Biosci 345802 PE) antibodies 
as well as 5μl anti-CD133 (Miltenyi 130-090-826 APC).  450μl of red cell lysis buffer 
(BD FACS lysing solution 06411) was then added and left for 10 minutes until the 
suspension became transparent.  The sample was added to a BD Trucount tube 
containing microbeads which allow determination of absolute cell number and 
concentration.  The sample was then diluted with phosphate buffered saline and 
processed using a BD FACSCanto flow cytometer.   
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The following gating strategy is in routine clinical use and generated a CD34+ cell 
count (cellsμl-1), CD133+ cell count (cellsμl-1) and the percentage of CD34+ cells that 


















Figure 3.1; Scatter plots demonstrating the gating strategy for the identification of 
CD34+ and CD133+ cells using side scatter (SSC-A), CD34, CD45 and CD133 
expression.  Each plotted dot represents a single cell. 
A Identification of CD34-positive low granularity cell population 
 




C  Partitioning of CD34 cells into CD133-positive and negative subsets (note 
logarithmic scale y-axis) – the scatter plot demonstrates a heterogeneous 
cell population which are taken from the gated population in B 
 
 
Data was analysed using GraphPad Prism software.  The use of parametric tests was 
only applied where statistical normality of the data was confirmed.  1 way ANOVA 
and unpaired t-tests were used to identify differences in cell densities between 
groups with post-hoc testing using Dunnet’s multiple comparison test.  All t-tests 
give 2-tailed p values.  
 
Identification of Mesenchymal Stromal Cells; 
Bone marrow, with its higher numbers of resident MSCs was used for the 
development of the multichannel flow cytometry algorithm.  Bone marrow was 
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obtained as per ethics committee approval whereby patients consented to the use 
of waste products from a primary total hip replacement.  2-5ml of liquid marrow 
was collected in 10ml RPMI/10% heparin by the orthopaedic surgeons performing 
the operation in the Avon orthopaedic centre.  The marrow sample was stored at 
21oC and processed within 24 hours.  The red cell population was removed by the 
addition of 20ml of Ammonium Chloride lysis buffer (0.15M ammonium chloride, 
0.01M potassium bicarbonate and 0.15mM EDTA in ddH2O).  The suspension was 
then centrifuged at 1800rpm for 10 minutes and washed in phosphate buffered 
saline.  The cells were then suspended in PBS at 2x106 cells ml-1 and incubated for 






CD44-PE Cy 7 
CD45-APC-H7 
 
The antibody-labelled cells were then washed in PBS and resuspended before being 




MSCs isolated by plastic adherence were used as a positive control in development 
of the algorithm.  Briefly; these cells were isolated from bone marrow samples 
acquired from the AOC in the same process as outlined above.  The donated bone 
marrow was broken up with a scalpel and washed in Hanks medium (Sigma H9269).  
The tissue (including bone, fat and cells) was then layered on Lymphoprep density 
gradient medium (Axis-Shield PoC AS) and centrifuged at 3000rpm for 30mins.  The 
mononuclear cell layer was carefully removed and suspended in Dulbecco's 
modified eagle's medium (DMEM, D5523, Sigma).  Red cells were subsequently 
removed by incubation in ammonium chloride lysis buffer (0.15M ammonium 
chloride, 0.01M potassium bicarbonate and 0.15mM EDTA in ddH2O) for 10 
minutes at 4oC and cell numbers calculated using trypan blue dye exclusion staining.  
The cells were then plated at 5x103cm-2 in DMEM supplemented with 10% foetal 
bovine serum (StemCell Technologies Inc., 06471) in vented culture flasks and 
passaged when reaching 80% confluence.  Cells isolated in this way have previously 
been analysed in our laboratories and meet all of the agreed international criteria 
for identification of MSCs (surface markers and differentiation potential) as per ISCT 
standards. 
 
At passage 3, cells were dehisced with trypsin EDTA (Cambrex, BE17-161E) and 
suspended in phosphate buffered saline at 2x106 cellsml-1.  The cells were then 
incubated with 5μl of the same 7 fluorochrome-conjugated antibodies listed above, 
washed and resuspended in PBS supplemented with goat serum to prevent 
adherence to plastic flow cytometry counting tubes. 
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Identification of MSCs in peripheral blood was attempted using the same antibody 
combination as above.  The samples were collected from patients attending the 
regional MS unit in accordance with Research Ethics Committee approval.  Samples 
were collected in EDTA, stored at 4oC and processed within 72 hours.  Ammonium 
chloride lysis buffer was added to 2ml of whole blood and the resulting cells washed 
and then incubated with the same panel of 7 fluorochrome-conjugated antibodies.  
The sample was analysed using the same BD FACSCanto flow cytometer and gating 





Detection of haematopoietic stem cells; 
Blood samples were obtained from 6 controls and 67 patients with MS.  Of those in 
remission and not on treatment, 7 had relapsing-remitting disease, 4 had primary 
progressive MS and 7 had secondary progressive disease.  One-way analysis of 
variance showed that there was no difference between circulating numbers of 
CD34+ cells in the blood of controls and the different subtypes of untreated MS (Fig 
3.2) with an F-test value of 1.06 (p=0.388), confirmed with Dunnett’s post-hoc 
testing which showed there were no statistically significant differences between 
any of the disease subtypes and the control group. 
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Figure 3.2; A CD34+ and B CD133+ cell counts/µl in controls, RRMS, PPMS and 








These results were replicated for CD133+ cells for which the F-test value was 0.85 
(p=0.48).  Similarly there was no difference in the proportion of CD34+ cells that 
were also positive for CD133 (data not shown) between the control group and the 
different types of MS (F=0.54; p=0.66). 
 
We next quantified the number of HSCs in the circulation of patients with RRMS 
taking four of the disease modifying therapies currently licensed in the UK (beta-
interferon, glatiramer acetate, natalizumab and alemtuzumab).  We first replicated 
work that has demonstrated mobilisation of CD34+ HSC subsets in patients receiving 
anti-CD49d monoclonal antibody for the treatment of MS.  Analysis of variance 
demonstrated statistically significant differences between groups (F=10.36; 
p<0.0001) and an unpaired students t-test a statistically significant difference 
between CD34+ cell levels in patients not receiving DMD and those receiving 
monthly Natalizumab infusions (2-tailed unpaired t-test, p=0.0046).  We also 
identified an increase in the numbers of circulating CD34+ cells in those taking 
glatiramer acetate compared with those on no DMD (2-tailed unpaired t-test, 
p=0.0197).  In multiparametric post-hoc testing (Dunnet’s multiple conversion test) 
the only statistically significant difference was between the group taking no DMD 






Fig 3.3; A CD34+ and B CD133+ cell counts/µl in patients with RRMS on no DMD, 






















The results for circulating numbers of CD133+ cells were similar though did not 
reach the same levels of statistical significance.  Group analysis using one-way 
anova showed a difference between the group means (F=5.890, p<0.0001) with 
Dunnets showing statistically significant difference between the no DMD and 
Natalizumab groups.  2-tailed unpaired t-tests confirmed a statistical difference 
between the no DMD and Natalizumab groups (p=0.0286).  There was no difference 
between the CD133+ cell counts in the no DMD and Glatiramer groups (p=0.3241) 
 
As has previously been described the proportion of CD34+ cells that were also 
CD133+ was reduced in those being treated with Natalizumab (unpaired t-test, 












Fig 3.3; % of CD34+ cells that are CD133+ in patients with RRMS on no DMD, beta-




















Finally we assessed circulating cell numbers in those undergoing clinically verified 
relapse warranting treatment with corticosteroid.  Unpaired t-tests demonstrated 
a statistically significant increase in circulating CD34+ cells in patients with RRMS 
undergoing relapse compared with those in remission regardless of whether they 
were receiving beta-inteferon (p=0.0161) or not (p=0.0383).  A small increase was 
also demonstrated in those experiencing a relapse whilst receiving monthly 
Natalizumab infusions compared to those taking the same medications but in 
remission, though results were not statistically significant due to a small sample size 
of the relapse group.  Unpaired t-tests also demonstrated a statistically significant 
difference in circulating numbers of CD133+ cells in those undergoing relapse taking 













Fig 3.4; A CD34+ and B CD133+ cell densities in patients experiencing relapse on no 




















No difference was seen in the proportion of CD34+ cells that were also positive for 
CD133 in patients undergoing relapse (data not shown). 
 
Detection of multipotent mesenchymal stromal cells; 
Characterisation of cultured MSCs by flow cytometry 
We first analysed laboratory-cultured MSCs - used as a positive control.  The MSCs 
were isolated from the mononuclear cell fraction of whole bone marrow by plastic 
adherence in the conventional manner.  The cells demonstrated homogeneous 












Fig 3.5; Selected flow cytometry scatter plots of cultured MSCs; A isotype controls 























Identification of MSCs in whole bone marrow 
We next analysed whole bone marrow.  The mononuclear population was gated 
according to forward scatter (cell size) and side scatter (cell granularity) in the 
conventional manner (Fig 3.6a).  The flow cytometry scatter plot of CD44 and 
CD105 expression demonstrates the presence of the same homogeneous 
CD44+CD105+ cell population (represented in green) which is visibly distinct from 
the remaining CD105- mononuclear cells (Fig 3.6b).  This population of cells are 
highlighted in green in Fig 3.6c in which they are demonstrably CD34-CD45- in 
keeping with the phenotype of MSCs.  Multiparametric analysis improves visual 
identification of the MSC population (Fig 3.7). 
 














Fig 3.7; Use of multiparametric scatter plots enables clearer visual separation 
of MSCs (green) from alternative MNCs (red) 
 
 
Identification of MSCs in blood samples from patients with MS 
We next attempted to identify the same population of cells in the peripheral blood 
samples of patients with MS including in those with ‘mobilised’ blood who were 
taking anti-CD49d antibody.  In Fig 3.7 there are two examples of flow cytometry 
scatter plots of peripheral blood samples from patients receiving Natalizumab.  The 




Fig 3.7; Flow cytometry scatter plots of blood samples obtained from patients 
taking Natalizumab for the treatment of RRMS – the same population of 
















We have successfully demonstrated mobilisation of HSCs into the peripheral blood 
during treatment with Natalizumab consistent with previously published work 
(Zohren et al., 2008).  Natalizumab is an antibody to the α4 subunit of α4β1 integrin, 
a cell adhesion molecule which through avidity to vascular cell adhesion molecule-
1 plays a key role in leucocyte trafficking from the peripheral blood into various 
components of the extracellular matrix, including to the CNS.  The clinical relevance 
of this mobilisation is not fully understood.  Recent work has shown that these cells 
retain full expansion and differentiation capacity, are more quiescent and are 
associated with differential effects on the frequency of circulating naive and 
memory B cells and of regulatory T cells which may explain correlation with 
amelioration of disease activity (clinical and radiological) (Mattoscio et al., 2015). 
 
We have also identified a similar elevation of circulating cell types in treatment with 
Glatiramer acetate which is a novel finding.  A putative mechanism for this effect is 
more difficult to envisage given the lack of biological activity of a co-polymer of 4 
amino acids which is thought to have its principal effect through immune system 
decoy.  Further interrogation is required to establish whether these cells have a 




We have also shown spontaneous mobilisation of HSCs into the circulation during 
a clinical relapse of MS, again with potential physiological relevance with regard to 
the endogenous inflammatory response.  The CD133+ cell subset have already been 
shown to possess neuroprotective properties in the context of other neurological 
disease (Bakondi et al., 2009) and to promote reparative potential through 
enhancement of progenitor cell survival (Bakondi et al., 2011).  Their presence in 
this context may therefore contribute both in attenuating tissue injury and 
promotion of endogenous repair mechanisms.  
 
We have also developed a novel means of detecting MSCs in the peripheral blood, 
although we did not detect peripheral blood mobilisation of MSCs under any of the 
conditions tested in either MS patients or control subjects.  Rare event detection in 
flow cytometry remains challenging.  The use of manual techniques including gating 
and visual identification of cell populations has associated challenges (Lugli et al., 
2010) and the volumes of non-mobilised peripheral blood required to isolate MSCs 
gives evidence of the rarity of the cells we are attempting to identify (Zvaifler et al., 
2000).  The ability to track stem cell numbers, phenotype and differentiation 
remains a key goal to understanding some of the effects of intravenous 
administration of stem cell populations in ours and other work.  Advances in flow 
cytometry technology including the development of mass spectrophotometry-
based cytometers (Bendall et al., 2012) and the ability to process complicated 
multiparametric data with automated computational methods may enable 
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confident and reproducible progress in reaching this goal in the future (Aghaeepour 
et al., 2013). 
 
Our results suggest a role for HSC mobilisation during treatment of MS and in acute 
relapse. Further work will be required to definitively determine whether 
mobilisation of endogenous stem cells correlates with recovery and is reparative or 
protective against future progression. The mechanisms underlying the putative 




















Following publication of the first phase III therapeutic trials in Multiple Sclerosis 
(MS) and their subsequent regulatory approval in the 1990s, attention turned to 
the matter of robust outcome measures to try and ensure reliable identification of 
therapeutic effect.  20 years later meaningful progress remains elusive and the 
design and validation of disability outcome measures continues to be a key 
requirement for all phenotypes of multiple sclerosis.  Within the primary 
progressive MS (PPMS) cohort this is particularly pertinent given an absence of 
clinical relapses or prominent MRI inflammatory activity, and provides significant 
barriers to robust therapeutic studies. 
 
The expanded disability status scale (EDSS), a 10-point ordinal scale based on 
neurological assessment and ambulation, was designed in the 1960s by John 
Kurtzke and modified 20 years later (KURTZKE, 1961; Kurtzke, 1983).  It is familiar 
(due to the accumulated decades of use) and, perhaps most crucially, is accepted 
by regulators as a measure of disease progression.  It does however have significant 
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shortcomings, widely discussed in the literature (Hobart et al., 2000).  It is an ordinal 
scale with significant functional intervals in its higher reaches, making progression 
partly a function of baseline score (Weinshenker et al., 1991).  Perhaps the most 
telling criticism is its inadequate sensitivity and responsiveness to changes in 
disease status (Whitaker et al., 1995).  In the context of PPMS it is insufficiently 
sensitive to enable detection of therapeutic effect in manageable cohort numbers 
over trial-length timeframes (Cottrell et al., 1999).  Despite its widely recognised 
shortcomings, its historical use, particularly in the context of the large (untreated) 
natural history studies which are no longer ethically possible, means it is probably 
indispensable in the context of design of updated outcome measures or surrogates.  
Alternative clinical scoring systems such as the MSFC have been developed due to 
these recognised shortcomings (Cutter et al., 1999; Polman and Rudick, 2010) but 
despite proven correlation with clinical (Rudick et al., 2009), imaging (Kalkers et al., 
2001) and patient-reported outcomes (Miller et al., 2000), it has not been 
acceptable to regulators as a primary endpoint in therapeutic studies, principally 
due to its dimensionless output. 
 
Alternatives to disability scales include composite endpoints such as disease activity 
free status, global measures of activities of daily living (such as Rankin scale/Barthel 
index), patient reported outcomes and other novel techniques such as kinematic 
recording.  None of these have thus far been validated.  Biomarkers are an 
attractive alternative if they are quantitative, reproducible and sensitive to small 
changes in disease status.  Whilst conventional MRI sequences have been validated 
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as a trial-level surrogate endpoint for relapse in RRMS (Sormani et al., 2009), they 
have not for disability progression or reversal. 
 
Neurophysiological assessment in the form of multimodal evoked potentials fulfil 
many of the criteria of an effective biomarker, and have been shown to have clear 
correlation with clinical disability in RR and SPMS in cross-sectional (Invernizzi et al., 
2011; Leocani et al., 2006) and longitudinal studies (Fuhr et al., 2001; Jung et al., 
2008; Schlaeger et al., 2012b).  A small study with not insignificant participant drop-
out has been published in the PPMS cohort and found similar correlations.  This 
work did not include direct comparison with imaging metrics (Schlaeger et al., 
2014a).  Of most interest from an imaging perspective are measures of axonal 
integrity/loss thought to underscore progressive disability; these include grey 
matter atrophy, cord atrophy, diffusion tensor imaging and magnetisation transfer 
ratio. 
 
The PPMS patient population provide a cohort that are unencumbered by clinical 
relapses, to some representing an ideal substrate in the search for alternative 
biomarkers.  A longitudinal study of evoked potential parameters in the PPMS 
cohort was conceived and initiated through the Neurology department at Frenchay 
Hospital in 2008.  Analysis of these data is here performed in a cross-sectional and 
longitudinal format.  Additionally, 27 of the 29 participants agreed to attend for MRI 
imaging (analysed by collaborators at the University of Nottingham) and repeat 
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clinical scoring to enable within-subject comparison of imaging and neuronal 
function (through evoked potential analysis).   
 
 
Materials and Methods 
 
Neurophysiological data was collected from 29 patients recruited from a regional 
MS centre.  Inclusion criteria included a definite diagnosis of PPMS according to the 
revised McDonald criteria of 2005 (Polman et al., 2005) and written informed 
consent.  Exclusion criteria included contraindications to transcranial magnetic 
stimulation and concomitant neurological disease.  The study was approved by the 
local ethics committee. 
 
Neurophysiological investigations were carried out at 0, 6, 12, 24, and 36 months 
and consisted of visual EPs (VEPs), motor EPs (MEPs) to adductor pollicis brevis and 
tibialis anterior, median and tibial somatosensory EPs (SSEPs) and brain stem 
auditory EPs (BSAEPs).  At each visit the subject also underwent clinical assessment 
by a Neurologist or MS specialty doctor; this consisted of the Expanded Disability 
Status Scale (EDSS) and the MS Functional Composite (MSFC).  The participants also 
completed the Rivermead Mobility Index (RMI) questionnaire.  27 of the 
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participants underwent single time-point MRI imaging and repeat clinical 
assessment consisting of the EDSS, MSFC and RMI. 
 
Data were analysed on a cross-sectional and longitudinal basis.  Comparison of the 
disability-correlation of neurophysiological and imaging parameters was completed 
in the 27 patients who consented to undergo MRI imaging.  The most recent 
complete neurophysiological dataset was used from each participant.  At the time 
of Neurophysiological assessment, the mean age of the participants was 52.4 years 
with a mean disease duration of 131.9 months.  At the time of MRI imaging the 
mean age was 54.3 years with a mean disease duration of 154.0 months.  The mean 
time lapse between Neurophysiological recording and MRI imaging was 671 days 
with a minimum of 254 days and a maximum of 1492 days.  There were 14 male 
participants and 13 female. 
 
For the longitudinal analysis, data were available from 27 patients who completed 
multiple visits.  Of the 29 patients recruited to the study, data was available for the 
purposes of this thesis from; 15 who completed all 5 visits/3 years of the study, 7 
who completed 4 visits/2 years, and 5 who completed 3 visits/1 year of the study.  
The mean age of participants at baseline was 50.1 years with a mean disease 





Evoked potentials – acquisition; 
All EPs were recorded using a Synergy Medelec machine according to International 
Federation of Clinical Neurophysiology (IFCN) guidelines (Deuschl and Eisen, 1999).  
Reference ranges were taken from the IFCN datasets except for VEPs in which 
reference ranges were calculated using mean and standard deviation values taken 
from internal laboratory recordings.  In brief; 
 VEPs were recorded 5cm anterior to the inion (Oz) with a reference 
electrode at Fz.  Full field pattern-reversal stimulation was presented to 
each eye at a frequency of 2 Hz and luminance of 85 candela/m2.  100 
sweeps were averaged and the p100 latency was identified from the 
resulting montage. 
 BSAEPs were recorded at Cz with the reference electrode placed over the 
ipsilateral mastoid.  Rarefaction clicks at 70 dB above hearing threshold 
were delivered at 10.1 Hz and 2000 sweeps averaged to allow identification 
of the waveforms III and V and calculation III-V. 
 SSEPs were recorded in both the upper and lower limbs.  For median nerve 
SEPs the recording electrodes were placed at Cv (over the 5th cervical 
spinous process) and Cc (2cm posterior to Cz and 7cm contra-lateral to the 
midline) with the reference electrodes positioned at antCv (over the supra-
glottal region) and Fz.  For tibial SEPs the recording electrodes were 
positioned at Lum (over the L2 spinous process) and Cc (as above) with 
reference electrodes over the umbilicus and at Fz.  Stimulation was 
performed at motor threshold with a 0.2ms square wave pulse at 3 Hz.  1000 
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sweeps were recorded for each potential and major components (p37 and 
lum for the posterior tibial SSEP (p37-lum) and N13 and N20 for median 
nerve SSEPs (N13-N20)) recorded from the resulting montage. 
 MEPs were generated using a Magstim unit with a 9cm circular stimulating 
coil.  Recording was made at the target muscles (adductor pollicis brevis in 
upper limbs; abductor hallucis in lower limb) and stimulation repeated until 
10 50-100uV responses had been recorded.  M- and F-waves were recorded 
for median (16 trials) and posterior tibial (10 trials) nerves and CMCT 
calculated using the formula; CMCT = MEP latency - (F-wave latency + M-
wave latency – 1)/2 where the M-wave is the distal motor latency. 
 
Evoked potentials – scoring; 
Conversion of the raw latency and amplitude data acquired during 
neurophysiological testing was based on a series of techniques that have previously 
been described in the literature.  Lower limb latency limits were adjusted for height 
as per Jung et al (Jung et al., 2008). 
 
The first was a ‘conventional’ ordinal scoring system modified from Fututake et al 
(Fukutake et al., 1998) by Leocani and colleagues (Leocani et al., 2006) that grades 
each evoked potential according to a 4 point scale; 
0 Normal 
1  Increased latency 
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2 Increased latency + morphological abnormality of a major component 
3 Absence of a major component 
Each potential was analysed independently by 2 Neurophysiologists and summated 
to give a score between 0 and 36 (bilateral VEP, BSAEP, UL SSEP, UL MEP, LL SSEP 
and LLMEP each scored 0-3). 
 
The second was a 6 point ordinal scale based solely on latency as described by Jung 
et al (Jung et al., 2008); 
0 Normal 
1 Pathological side difference of latency 
2 Latency of upper limit of normal (mean + 2.5 standard deviations) (ULN) 
to 1.1 x ULN or >50% side difference of amplitude 
3 Latency of 1.1-1.3 x ULN 
4 Latency >1.3 x ULN 
5 Absent EP component 
Each potential was scored and summated to give a score of 0 - 60 (2 sides, 6 EPs, 5 
points per EP).   
The data was also converted to z-scores for each EP whereby; 
z = (actual latency – mean control latency) / control standard deviation 
The z-scores were then summed (the sum-z score).  The use of z-scores is 
complicated by absent EP components.  Various techniques have been employed 
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to circumvent this problem.  In order to preserve the relevance of an absent 
component and to reflect greater pathway dysfunction we substituted absent EPs 
with the cohort max z-score + 1. 
 
Finally, the number of abnormal EPs divided by the number of recorded EPs was 
calculated yielding the Path-Q score as performed by Schlaeger and colleagues 
(Schlaeger et al., 2014a) 
 
MR Imaging; 
All consenting participants were imaged using a Phillips 3T MR scanner.  Brain 
imaging was recorded using a 32 channel coil and 1mm3 voxels.  Sagittal 3D T1-
weighted fast gradient echo sequences were used for volumetric analysis and fluid 
attenuation inversion recovery for white matter lesion quantification.  Spinal 
imaging was performed using a Sense Spine Coil.  Cross-sectional areas at 4 spinal 
levels were calculated from T2 balanced gradient echo sequences using contrast 
level appearance. 
 
All MRI parameters were calculated by collaborators at the University of 
Nottingham who were supplied with copies of the raw data in anonymised format.  





Cross-sectional and longitudinal correlations were calculated using Spearman’s 
correlation coefficient (rho/ρ) with consensus statistical significance set at p values 
of 0.05 and 0.01.  Data was analysed using Prism software.  Where multiple values 
were taken from the same participant multilevel statistical modelling was employed 





Cross sectional analysis; neurophysiology 
Correlation of Neurophysiology-derived global scores of CNS dysfunction with 
clinical disability metrics revealed strong correlation consistent with previous work 
in MS populations.  Of the global disability metrics, EDSS better correlates with the 
various methods of EP analysis (rho/ρ = 0.65- (-)0.71) than does the MSFC (rho/ρ = 
0.47- (-)0.50) (Fig 4.1).  Elements that reflect/quantify mobility including the RMI 
and ambulatory threshold (a component of the EDSS), both showed some 
statistically significant correlation with the EP scores – this is unsurprising given that 
the EDSS is heavily weighted towards mobility in the upper echelons of the scale.  
Perhaps surprisingly, whilst there was no correlation of the neurophysiological 
scores with disease duration, there was some correlation with age of the patient 
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(Table 4.1).  Of the different evoked potential scoring methods, that based on z-
transformed latencies showed the strongest correlation with the EDSS compared 


















Figure 4.1; Scatter plots of the EDSS versus the 4 different neurophysiology-based 
scoring methods; A ordinal 4-point score (rho = 0.65, p = 0.0003); B ordinal 6-point 
score (rho = 0.67, p = 0.002); C Summed z-score (rho = -0.71, p < 0.0001); D Path-Q 
score (rho = 0.67, p = 0.0002).  Each dot represents 1 of the participants.  Line of 











































































Table 4.1; Spearman’s correlation coefficients (rho/ρ) of the four different 
neurophysiological scoring methods and patient demographics, EDSS, ambulation 
(distance covered within EDSS assessment), MSFC and Rivermead Mobility Index 
(RMI).  P-values of 0.05 or less are indicated in bold red, values of 0.01-0.05 are 
indicated in red. 
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The pathways interrogated in each of the evoked potentials are differentially 
affected both between and within subjects.  Some of the evoked potentials (such 
as MEP and VEP) have been shown to have greater change over time and better 
correlation with disease metrics (Fuhr et al., 2001).  Correlations of the component 
parts of the global evoked potential scores and varying combinations thereof with 
the clinical metrics were next calculated (Table 4.2). 
 
In this dataset, the performance of individual evoked potentials as correlates of 
clinical scores of disease severity depended on the scoring method employed.  
Using a 4-point ordinal scale (calculated according to amplitude/morphology and 
latency), the MEP correlated best with the EDSS (rho=0.59, p=0.002) though this 
was less than when using a global score (derived from all 4 evoked potentials).  
When using a more sensitive 6-point scale based only on latency (rho=0.75, 
p<0.0001) or z-transformed latencies (rho=0.72, p<0.0001), combined upper and 
lower limb SSEPs provided the best correlation with EDSS and this was superior to 
the performance of global scores. 
 
Using the 4-point ordinal scale or the z-transformed latencies, exclusion of evoked 
potentials from the global score did not improve on performance.  However when 
using a 6-point ordinal scale based on latency, combining the VEP score with the 
lower limb MEP and both upper and lower limb SSEP improved correlation with the 
142 
 
EDSS (excluding the BSAEP and upper limb MEP) compared with the global score 
(rho=0.78, p<0.0001). 
 
Correlation of individual evoked potential scores with the MSFC was improved by 
excluding the PASAT from the clinical score but, as with global evoked potential 















Table 4.2; Spearman’s correlation coefficients (rho/ρ) of clinical measures 
(including selected sub-components) and evoked potential scores (calculated 
according to ordinal scores and z-transformed latencies as previously described) 
either individually or in various combinations.   
The clinical scores include the average of the 9HPT and T25FW (MSFC without 
paced serial addition test).   
The evoked potentials used in the analysis consist of motor-evoked potentials 
(MEP) and somatosensory evoked potentials (SSEP) including those within the 
upper limbs only (UL) and lower limbs only (LL), and the visual evoked potentials 
(VEP), individually and in various combinations.   






 EDSS Ambulation MSFC 9HPT T25FW 9HPT/T25FW 
 rho p Rho p rho p rho p rho p rho p 
4-point ordinal scale; latency and morphology         
MEP 0.5887 0.0016 -0.53 0.0054 -0.394 0.0465 -0.324 0.1058 -0.320 0.11 -0.3585 0.0721 
SSEP 0.4766 0.0138 -0.379 0.0561 -0.427 0.0298 -0.448 0.0215 -0.261 0.1972 -0.4666 0.0163 
SSEPLL 0.3343 0.0951 -0.204 0.3167 -0.188 0.3584   -0.073 0.7219 -0.1692 0.4086 
VEP 0.3654 0.0664   -0.094 0.648       
5-point ordinal scale; latency only       
MEP 0.5072 0.0082 -0.371 0.0623 -0.271 0.1806 -0.292 0.1479 -0.275 0.1748 -0.3183 0.113 
MEPUL 0.434 0.0267   -0.221 0.2771 -0.288 0.1538   -0.2629 0.1945 
MEPLL 0.592 0.0014 -0.514 0.0072 -0.416 0.0347   -0.283 0.1616 -0.3932 0.0469 
SSEP 0.7492 <0.0001 -0.729 <0.0001 -0.534 0.0049 -0.558 0.0031 -0.510 0.0078 -0.606 0.001 
SSEPUL 0.5109 0.0077   -0.414 0.0356 -0.553 0.0034   -0.5471 0.0038 
SSEPLL 0.5097 0.0078 -0.501 0.0092 -0.378 0.0566   -0.306 0.1281 -0.3015 0.1344 
VEP 0.3162 0.1155   -0.217 0.2866       
MEPLL/SSEP 0.7733 <0.0001 -0.72 <0.0001 -0.535 0.0049 -0.535 0.0049 -0.489 0.0112 -0.5906 0.0015 
MEPLL/SSEP/VEP 0.7799 <0.0001 -0.704 <0.0001 -0.564 0.0027 -0.532 0.0051 -0.502 0.0089 -0.5965 0.0013 
z-transformed latencies      
MEP -0.654 0.0003 0.5287 0.0055 0.427 0.0296 0.3696 0.0631 0.3237 0.1067 0.401 0.0423 
MEPUL -0.552 0.0035   0.3121 0.1206 0.3566 0.0738   0.3703 0.0626 
MEPLL -0.637 0.0005 0.5547 0.0033 0.4209 0.0322   0.3056 0.129 0.3859 0.0515 
SSEP -0.715 <0.0001 0.731 <0.0001 0.5439 0.0041 0.5829 0.0018 0.4992 0.0094 0.6342 0.0005 
SSEPUL -0.54 0.0044   0.417 0.034 0.5819 0.0018   0.5806 0.0019 
SSEPLL -0.511 0.0076 0.4989 0.0095 0.3537 0.0763   0.2957 0.1424 0.2773 0.1702 








Cross-sectional analysis; imaging 
In cross-sectional analysis of imaging parameters, only spinal cord area correlated 
to any degree with clinical motor disability measures (Table 4.3).  The C5/6 cross 
sectional area (CSA) was the only measure to correlate with the EDSS (rho=0.54, 
p=0.02), as well as the only to correlate with mobility threshold, MSFC and 
9HPT/T25FW.  In contrast to the evoked potential scores, correlation was better 
with the MSFC (rho=0.63, p=0.006).  Whilst the C2/3 CSA correlated well with the 
9HPT (rho=-0.73, p=0.003), none of the imaging parameters correlated with the 
T25FW. 
 
The only objective clinical score of cognitive function tested in this study was the 
PASAT.  Volumetric imaging parameters showed a trend towards correlation with 





Table 4.3; Table of Spearman correlation coefficients (ρ/rho) of clinical measures (including selected sub-components) and imaging parameters.  
Clinical parameters as in table 4.2 with the addition of the paced serial addition test.  Abbreviations; EDSS = expanded disability status scale; 
MSFC = multiple sclerosis functional composite; 9HPT = 9-hole peg test; T25W = timed 25 foot walk; PASAT = paced serial addition test; GMV = 
grey matter volume; WMV = white matter volume; BV = brain volume; TIV = total intracranial volume; CSA = cross-sectional area.  P-values of 
0.05 or less are indicated in bold red, values of 0.01-0.05 are indicated in red. 
 EDSS  Ambulation  MSFC  9HPT  T25FW  9HPT/T25FW  PASAT 
 rho p  rho p  rho p  rho p  rho p  rho p  rho p 
GMV (litres) 0.05 0.83  0.02 0.93  0.05 0.85  -0.09 0.72  -0.19 0.43  -0.17 0.48  0.43 0.07 
WMV (litres) -0.01 0.98  0.08 0.74  0.12 0.62  -0.12 0.63  -0.18 0.46  -0.12 0.63  0.49 0.03 
BV (litres) 0.05 0.85  0.02 0.94  0.05 0.85  -0.08 0.74  -0.17 0.50  -0.18 0.47  0.45 0.06 
BV/TIV -0.12 0.64  0.23 0.34  0.27 0.27  -0.05 0.84  -0.07 0.78  0.08 0.76  0.42 0.07 
Lesion Load (litres) 0.28 0.25  -0.34 0.16  -0.27 0.26  0.20 0.41  0.25 0.31  -0.25 0.30  -0.18 0.47 
Lesion Load (%) 0.26 0.29  -0.33 0.16  -0.30 0.21  0.22 0.37  0.24 0.33  -0.24 0.31  -0.29 0.23 
C2/3 CSA (mm2) -0.41 0.14  0.48 0.09  0.53 0.054  -0.73 0.003  -0.30 0.29  0.49 0.08    
C5/6 CSA (mm2) -0.54 0.02  0.58 0.015  0.63 0.006  -0.52 0.03  -0.15 0.56  0.51 0.04    
T4/5 CSA (mm2) -0.35 0.16  0.30 0.23  0.42 0.09  -0.47 0.049  -0.10 0.68  0.28 0.26    
T9/10 CSA (mm2) -0.29 0.25  0.28 0.26  0.35 0.15  -0.35 0.15  0.00 0.99  0.20 0.43    
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Post hoc analysis with comparison of median-split groups according to age and 
disease duration was undertaken, demonstrating greater correlation of EDSS and 
EP score in older participants and those with longer disease duration for the 
majority of the scoring techniques (Tables 4.4 and 4.5).  Indeed, restricting 
calculations to include only those in the oldest 50% of the cohort and the 50% with 
the longest disease duration improved correlations (across all EP scoring methods) 
compared with calculations using the entire dataset.   
 
The EP scores demonstrated more sporadic correlation with the MSFC and to a 




Table 4.4; Spearman’s correlation coefficients (ρ/rho) for median-split subgroups 
(according to disease duration) of EDSS and MSFC and the neurophysiological 
scores as previously described.  P-values of 0.05 or less are indicated in bold red, 




 EDSS  MSFC 
 rho p  rho p  rho p  rho p 
 Lower half  Upper half  Lower half  Upper half 
4-point ordinal scale; latency and morphology     
Global score 0.4548 0.1184  0.8669 0.0001  -0.4288 0.1438  -0.4814 0.0958 
            
5-point ordinal scale; latency only    
Global score 0.4881 0.0906  0.8396 0.0003  0.449 0.1237  -0.4077 0.1667 
MEPLL/SEP 0.709 0.0067  0.8211 0.0006  -0.5069 0.0771  -0.4545 0.1186 
MEPLL/SEP/VEP 0.6167 0.0248  0.8994 <0.0001  -0.5007 0.0814  -0.5482 0.0524 
            
Sum of z-transformed latencies  
Global score -0.5583 0.0474  -0.8118 0.0008  0.467 0.1076  0.3846 0.1944 
SEP -0.8052 0.0009  -0.6017 0.0296  0.6484 0.0165  0.2473 0.4154 
            
Path Q 0.4908 0.0886  0.8527 0.0002  -0.4318 0.1406  -0.5465 0.0533 
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Table 4.5; Spearman’s correlation coefficients (ρ/rho) for median-split subgroups 
(according to age of patient) of EDSS and MSFC and the neurophysiological scores 
as previously described.  P-values of 0.05 or less are indicated in bold red, values of 




Longitudinal analysis; neurophysiology 
An incomplete dataset was available to me for the purposes of this thesis.  Of the 
29 participants of the study, the data for up to 16 was available from the last/fifth 
visit (V5). Numbers included in each of the analyses are indicated in the tables 
below. 
 
 EDSS  MSFC 
 rho p  rho p  rho p  Rho p 
 Lower half  Upper half  Lower half  Upper half 
4-point ordinal scale; latency and morphology     
Global score 0.3437 0.2501  0.9382 <0.0001  -0.3126 0.2984  -0.5317 0.0615 
            
5-point ordinal scale; latency only     
Global score 0.2348 0.44  0.9495 <0.0001  -0.1909 0.5322  -0.6253 0.0223 
MEPLL/SEP 0.6179 0.0244  0.903 <0.0001  -0.3807 0.1994  -0.4821 0.0952 
MEPLL/SEP/VEP 0.5318 0.0614  0.931 <0.0001  -0.3576 0.2302  -0.6704 0.0122 
            
Sum of z-transformed latencies     
Global score -0.3315 0.2685  0.93 <0.0001  0.2033 0.5053  0.5549 0.049 
SEP -0.6266 0.0219  -0.7446 0.0035  0.3791 0.2014  0.4231 0.1497 
            
Path-Q 0.2328 0.4441  0.935 <0.0001  -0.163 0.5948  -0.6363 0.0194 
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Direct correlation of changes in the neurophysiological scores and changes in the 
EDSS over all time intervals did not show any consistent patterns of correlation or 
changes in those patterns over time (Table 4.6).  Whilst there are some statistically 
significant correlations, notably for the global scores in the first year of the study, 
these are generally isolated findings.  Of note, there are no significant correlations 
seen that include changes in disability at the end of the study (V5).  This is in 
contrast to the cross-sectional data that suggested that correlation was greater in 
those who had had the disease for longer and/or were older. 
 
In order to assess the predictive potential of changes in Neurophysiological 
parameters, correlation of the changes over 6 (V1-V2) (Table 4.7) and 12 (V1-V3) 
(Table 4.8) months with future EDSS (at V3, V4 and V5) and EDSS change from 
baseline at V3, V4 and V5 was calculated.  Changes over the first 12 months seemed 
to be more informative then changes in the first 6 months only with regard to 
predicting future disability but again statistically significant results were sporadic.  
The changes appeared to more predictive of shorter term changes in disability (at 







Table 4.6; Spearman’s correlation coefficients (ρ/rho) of change in 
Neurophysiology score vs change in EDSS both from baseline (V1) and interval 
changes.  4-point ordinal scale and summed z-transformed latencies (as previously 
described) are both illustrated including subcomponents thereof.  P-values of 0.05 
or less are indicated in bold red, values of 0.01-0.05 are indicated in red. 
 
  4-point ordinal scale 
 
Sum of z-transformed latencies 
  Global MEP LL SEP VEP 
 
Global MEP LL SEP LL VEP 
      
 
    
V1-V2 n 21 21 21 21 
 
22 22 22 22 
 Rho -0.115 0.043 -0.023 -0.103 
 
-0.361 -0.178 -0.036 -0.048 
 p 0.621 0.852 0.920 0.658 
 
0.099 0.428 0.874 0.832 
V1-V3 n 20 20 20 20 
 
23 23 23 24 
 Rho 0.501 0.514 -0.270 0.021 
 
0.175 0.625 -0.099 -0.064 
 p 0.025 0.021 0.250 0.932 
 
0.425 0.001 0.655 0.766 
V1-V4 n 18 17 18 18 
 
20 20 20 20 
 Rho 0.258 0.342 0.040 0.189 
 
0.544 0.275 0.497 0.115 
 p 0.301 0.179 0.874 0.454 
 
0.013 0.240 0.026 0.628 
V1-V5 n 12 12 12 12 
 
13 13 13 13 
 Rho -0.0073 0.2354 -0.2648 0.0885 
 
0.2264 0.0679 -0.1443 0.2292 
 p 0.9821 0.4614 0.4055 0.7845 
 
0.4570 0.8255 0.6380 0.4512 
      
 
    
      
 
    
V2-V3 n 20 20 20 20 
 
23 23 23 24 
 Rho 0.568 0.409 -0.008 0.233 
 
-0.052 0.239 0.188 0.156 
 p 0.009 0.073 0.975 0.323 
 
0.815 0.272 0.390 0.467 
V3-V4 n 20 19 20 20 
 
22 22 22 22 
 Rho -0.28 -0.25 -0.26 0.06 
 
0.10 -0.20 0.16 -0.08 
 p 0.23 0.31 0.26 0.81 
 
0.64 0.36 0.49 0.72 
V4-V5 n 14 13 14 14 
 
15 15 15 15 
 Rho -0.040 0.087 -0.019 -0.432 
 
0.091 0.001 0.050 0.373 
 p 0.893 0.776 0.949 0.123 
 




Table 4.7; Spearman’s correlation coefficients (ρ/rho) of change in 
Neurophysiology scores from V1-V2 (0-6 months) vs EDSS both at timepoints V3, 
V4 and V5 and the change in EDSS from baseline at V3, V4 and V5.  P-values of 0.05 






  4-point ordinal scale  Sum of z-transformed latencies 
  Global MEP LL SEP VEP  Global MEP LL SEP LL VEP 
           
V3 EDSS n 24 24 24 24  25 25 25 25 
 Rho 0.224 -0.010 -0.043 0.318  0.422 0.239 0.082 0.357 
 p 0.293 0.962 0.842 0.130  0.036 0.249 0.698 0.080 
V4 EDSS n 21 21 21 21  22 22 22 22 
 Rho 0.247 0.029 0.201 0.073  0.004 -0.076 -0.003 0.294 
 p 0.281 0.900 0.383 0.753  0.986 0.737 0.989 0.184 
V5 EDSS n 16 16 16 16  16 16 16 16 
 Rho -0.0377 -0.1399 0.1873 0.5543  0.0857 0.0955 -0.0887 0.3459 
 p 0.8898 0.6054 0.4872 0.0259  0.7524 0.7249 0.7438 0.1894 
           
V1-V3 n 22 22 22 22  23 23 23 23 
 Rho -0.207 0.044 -0.203 -0.156  0.028 -0.099 0.196 -0.039 
 p 0.355 0.847 0.366 0.489  0.899 0.653 0.371 0.861 
V1-V4 n 19 19 19 19  20 20 20 20 
 Rho -0.079 0.162 0.074 -0.324  -0.291 -0.299 -0.095 -0.092 
 p 0.748 0.508 0.765 0.177  0.213 0.200 0.691 0.698 
V1-V5 n 14 14 14 14  14 14 14 14 
 Rho -0.412 -0.082 -0.049 -0.011  -0.572 -0.494 -0.496 -0.089 
 p 0.143 0.782 0.867 0.970  0.033 0.073 0.071 0.763 
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Table 4.7; Spearman’s correlation coefficients (ρ/rho) of change in 
Neurophysiology scores from V1-V3 (0-12 months) vs EDSS both at timepoints V3, 
V4 and V5 and the change in EDSS from baseline at V3, V4 and V5.  P-values of 0.05 
or less are indicated in bold red, values of 0.01-0.05 are indicated in red. 
 
  4-point ordinal scale  Sum of z-transformed latencies 
  GEPS MEP LL SEP VEP  Sum-z MEP LL SEP LL VEP 
           
V3 EDSS n 22 22 22 22  25 25 25 25 
 Rho 0.450 0.234 0.371 0.108  -0.014 0.108 -0.026 0.426 
 p 0.036 0.294 0.089 0.632  0.947 0.608 0.903 0.034 
V4 EDSS n 21 21 21 21  22 22 22 22 
 Rho 0.680 0.473 0.495 0.077  0.330 0.219 0.142 0.535 
 p 0.001 0.030 0.023 0.739  0.134 0.327 0.530 0.010 
V5 EDSS n 16 16 16 16  16 16 16 16 
 Rho 0.344 0.195 0.579 0.042  0.256 0.126 0.254 0.525 
 p 0.193 0.469 0.019 0.878  0.340 0.643 0.342 0.037 
           
V1-V3 n 20 20 20 20  23 23 23 23 
 Rho 0.501 0.514 -0.270 0.021  0.175 0.625 -0.099 -0.063 
 p 0.025 0.021 0.250 0.932  0.425 0.001 0.655 0.774 
V1-V4 n 19 19 19 19  20 20 20 20 
 Rho 0.602 0.629 0.069 -0.152  0.365 0.478 -0.077 0.112 
 p 0.006 0.004 0.780 0.534  0.113 0.033 0.748 0.637 
V1-V5 n 14 14 14 14  14 14 14 14 
 Rho 0.297 0.341 -0.113 0.428  0.369 0.524 -0.096 0.064 









In keeping with previous work in both the general MS population (Invernizzi et al., 
2011; Leocani et al., 2006) and specifically the PPMS population (Schlaeger et al., 
2014a) we have shown statistically significant cross-sectional correlation between 
evoked potential-based scoring methods and clinical parameters of disability.  This 
is the largest cohort to date of interrogation of patients with PPMS, demonstrating 
marginally superior levels of correlation compared with earlier work.   
 
In seeking to test for variation in correlation within the group, restriction of the 
dataset to patients who were either older or had experienced longer disease 
duration resulted in levels of correlation not before documented in the MS 
literature.  The explanation for this finding is not immediately clear.  When splitting 
the cohort according to age, the older group had a greater range of disability 
according to EDSS and a lower mean disability whereas when the patients were split 
according to disease duration those that had had the disease for longer had a 
narrower range of disability with an equivalent mean EDSS.  In the only other 
comparably-sized study (Schlaeger et al., 2014a), whilst the highest levels of 
correlation were seen at the study endpoint, the lower numbers included in this 
data due to participant drop out makes the findings less robust, and the levels of 




Within-subject comparison of the relative strength of correlation of both 
neurophysiological and imaging parameters with disability measures has not 
previously been achieved in a PPMS cohort.  The only imaging metric to correlate 
with the EDSS was the C5/6 cross sectional area with the strength of correlation 
inferior to that achieved with evoked potential-based scoring systems.  This finding 
adds to the weight of evidence suggesting that evoked potentials, essentially a 
measurement of the function of eloquent neural pathways, shows greater promise 
in providing a surrogate for disability in PPMS than do established imaging 
outcomes. 
 
The results of the longitudinal analysis are not all in keeping with previous study of 
the PPMS population.  With the caveat of an incomplete dataset, the apparent 
disconnect between high levels of correlation in cross-sectional analysis and 
correlation in the changes of clinical and neurophysiological parameters over time 
is somewhat disappointing.  Whilst statistically significant correlation of changes in 
the latency-based z-score and EDSS were seen over the first 2 years of the study, 
there is no pattern or consistency to the results and a loss of correlation at the study 
endpoint.  This is in keeping with previous work which identified a ‘trend’ in 
longitudinal correlation without reaching statistical significance over a 3 year period 
(Schlaeger et al., 2014a).  The predictive capacity of changes in Neurophysiological 
scores over the first 6-12 months was less than this study identified, though 
changes over the longer period seemed to provide more robust prediction, though 
still without pattern or consistency. 
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The results here suggest that z-transformed latencies are superior to ordinal scales 
and to categorical scores (giving mean number of abnormally prolonged EPs) as 
potential surrogates of disability within the PPMS population.  This is likely to be 
due to the loss of data associated with categorisation of values in the ordinal scales.  
If these outcomes are to be translated to the clinical setting, regulator concerns 
regarding the meaning of output scores to the patient remain to be reconciled.  As 
scoring methods increase in complexity and move away from single, simple, 
clinically relevant parameters the problem becomes more acute.  Single parameter 
scores would be a move towards overcoming this conundrum, and in that domain 
measurements of the functionality of long-tracts would appear to provide the most 
hope.  Previous work in the PPMS population has suggested that upper limb MEP 
and tibial SSEP could be used in place of a full 3 or 4 modal evoked potential 
protocol without losing substantial information (Schlaeger et al., 2014a); in this 
work however, the SSEP alone was equivalent to the globally-derived score in 
strength of correlation with EDSS.  Whilst it does not measure a clinically 
identifiable outcome for the patient and does not involve calculation of a composite 
score, it does involve the dimensionless z-score.  The inherent problems of using a 
single EP include the difficulty once electrical conduction within the pathway falls 
below a threshold and there is loss of output with no potential for further variability 
thereof. 
 
The EDSS is heavily weighted towards mobility, being almost wholly dependent on 
ambulation beyond the threshold score of 4.0.  Whilst there are some elements of 
157 
 
disability that are neglected or underrepresented in the scale, for the majority it 
provides a useful metric of the severity of disease.  It is therefore not surprising that 
both neurophysiological and imaging parameters that measure the long tracts 
(both pyramidal fibres and sensory pathways that pass through the cervical cord) 
provide the most robust correlation with the EDSS.  Given the historical use of the 
EDSS in prospective comparator populations, it remains the scale to which 
surrogate markers are likely to have to compare before use in clinical studies is 
ratified.  Measures of the spinal cord and function of these long tracts are therefore 
likely to be central to the eventual solution. 
 
Study limitations include significant variation in the disease duration at the time of 
recruitment, introducing structural weakness to data analysis and limiting the 
extrapolation and indeed to some extent the utility of the results.  Further 
strengthening of findings could also have been achieved by imaging patients at the 
same time as recording the evoked potentials which would also enable assessment 
of direct correlation between imaging and evoked potentials.  With regards to the 
longitudinal data there was some participant dropout and problems with missing 
data, likely a function of the duration of the study.  Whilst neurophysiology is 
generally extremely reproducible, particularly with internationally accepted 
standards/minimum criteria, MEP does introduce a degree of operator variability 
and needs to be controlled for in future use.  Finally, whilst DTI sequences were 
acquired in the MRI protocol these were not available to me for the purposes of 
this thesis.  Preliminary work looking at correlation of fractional anisotropy with 
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disability in the general MS population has been promising and would certainly 
warrant future interrogation. 
 
Future work should seek to test these correlations in significantly sized cohorts 
including those undergoing large scale therapeutic studies.  Assessment of critically 
eloquent pathways that underscore motor disability warrant particular attention, 
with the potential for composite scores using both imaging and functional electrical 
studies – though with the caveat of difficulty in reconciling the concept with drug 



















Whilst there has been significant progress in the efficacy and most prominently the 
mode of delivery of drugs that target increasingly specific inflammatory 
components critical to the development of MS over the last 2 decades, the disease 
remains far from a curable condition.  Furthermore, potent immunosuppression 
even of very specific targets within the immune system is not achieved without 
significant risk of potentially fatal complications.  The disconnect between 
inflammation and the neurodegeneration that ultimately underlines disability has 
been widely discussed and continues to limit the success of increasingly potent 
immunosuppressants.   
 
Neuroprotection, immunomodulation and cell replacement, all demonstrable 
properties of adult multipotent mesenchymal stem cells offer further therapeutic 
potential that may help to address not just the inflammatory disease component 
but also the critical neuronal attrition that underscores patient disability.  Much 
work has been done over the last decade and more to elucidate these properties; 





Animal models of inflammatory neurological pathology have yielded many clues to 
the mode of activity of adult stem cells, predominantly MSCs.  Detailed knowledge 
of their location/mobilisation, function and properties in man however is lacking.  
Whilst there are many similarities between EAE and MS, there remain critical 
pathophysiological differences limiting extrapolation from laboratory work to the 
clinic and prompting some of the work described in this thesis.   
 
Mobilisation of haematopoietic stem cells in the context of anti-CD49d activity has 
been demonstrated and may represent an unrecognised therapeutic contribution 
in its clinical use.  Alongside replicating these earlier findings, we have here shown 
that cells expressing the same marker are present in the circulation in higher 
numbers in patients with MS undergoing clinical relapse than those in remission.  
We have also demonstrated the presence of release of the CD133+ subset (with 
greater proliferative and differentiation potential) within this population of cells, in 
those undergoing relapse.   
 
It is in some respects unsurprising that cells with regenerative capacity are released 
as part of the inflammatory cascade that is so prominent in MS but this has not 
before been demonstrated.  The precise therapeutic contribution of these cells in 
MS in humans is unknown, but the regenerative potential of the cells in-vitro as well 
as in-vivo (in the context of animal models) is well documented, including the 
potential for regenerative contribution of haematopoietic stem cells to non-




Alongside identification of haematopoietic stem cells in peripheral blood samples 
we also attempted to isolate stromal stem cells in the form of multipotent 
mesenchymal stem cells.  Whilst the detection of these cells within the bone 
marrow niche was readily achieved using a novel cytometric algorithm, detection 
in the peripheral blood stream where they are present in lower numbers proved 
challenging, including in subjects in whom other stem cell subsets had been 
mobilised either in the context of relapse or administration of an endogenous cell 
mobilising agent.   
 
With time, inevitable technological progress in rare event detection using 
multichannel cytometric techniques will enable more robust identification of these 
circulating cells.  Clearly this will have significant therapeutic utility in enabling 
indirect monitoring of the intra-venous infusion of MSCs for a wide range of both 
neurological and non-neurological conditions.  Direct evidence for the dynamic 
monitoring and eventual fate of intra-venously delivered MSCs is likely to depend 
upon the development of labelling technology that is firstly safe in human use, and 
secondly enables identification by localisation techniques at the single cell level, a 
highly technically challenging objective. 
 
Additional evidence to support the theory of multipotent mesenchymal stromal cell 
mobilisation and contribution to the pathophysiology of restorative processes in 
the context of MS, comes from identification of cells expressing relevant cell 
markers within lesions in MS-affected brain tissue.  Consistent with the 
identification of subsets of stem cells released during periods of inflammatory 
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activity, these cells were more readily identified in active lesions in patients with 
progressive disease - either primary progressive disease or following an earlier 
relapsing- remitting course.  The cells in question were found in parallel with the 
inflammatory infiltrate of activated microglia both throughout active lesions and at 
the ‘active’ rim at the periphery of chronic active lesions.  None were identified in 
the brains of control subjects who did not have neurological or systemic 
inflammatory pathology.   
 
The difficulty in identifying cells with no single defining characteristic and in whom 
cell surface molecule expression varies according to lineage commitment is self-
evident.  Nonetheless, the dual expression of at least two proven markers, in 
tandem with the absence of markers of the alternative cellular components of 
white matter brain tissue, provides not insignificant evidence to support this 
hypothesis.  Whilst the level of infiltration of areas of disease activity within the CNS 
of patients with MS was greater than might have been expected, this is not 
something that has previously been explored in the neuroscientific literature, and 
is not out-with the realms of pathophysiological possibility.  The ability of these cells 
to home to sites of tissue injury is well established, as are a multitude of properties 
that have protective and restorative capacity.  Indeed it is hypothesised that, 
contrary to the traditionally held view of supportive stromal function within the 
bone marrow niche, the principal role of these cells is to protect and repair tissue 
throughout the human body.  It is therefore in many ways of no surprise 





The ability to detect therapeutic gain has long challenged those working within the 
field of multiple sclerosis, as in many other neurodegenerative conditions which 
progress over many years.  Whilst the inflammatory component of the disease is 
relatively easy to quantify, measure and record, we have discussed how its 
fundamental relationship to progressive disability is at best questionable.  The 
recent development of the outcome measure of ‘no evidence of disease activity’ 
(both clinically and radiologically) makes attempts to circumvent some of these 
problems but again remains purely a marker of inflammatory activity.   
 
We have shown that Neurophysiological markers of CNS integrity/function are 
superior to established imaging metrics as a surrogate marker of disability as 
measured by the EDSS in primary progressive MS.  Whilst the EDSS is an imperfect 
cornerstone on which to base these judgements, historical use of the EDSS and the 
practical difficulties associated with contemporary natural history studies means 
that it will necessarily remain central to such endeavours.   
 
High levels of correlation between the EDSS and scores based on evoked-potential 
neurophysiological parameters were identified in cross-sectional analysis, with 
particularly high levels seen in patients who were older and had had the disease for 
a longer duration.  Whilst changes in the evoked-potential based scores did not 
correlate systematically with changes in the EDSS, there were areas of promise.  The 
use of z-transformed latencies which continue to capture deterioration of neuronal 
pathways up to the point of conduction failure would appear to represent the most 
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promising measure for the purposes of detection of disease progression in 
established disease.  Whilst the correlation over the longest intervals was 
disappointing, this may have been a factor of a reduction in sample size due to 
participant drop out and an incomplete dataset.   
 
The ideal method of scoring the neuronal dysfunction captured in 
neurophysiological assessment remains to be definitively established.  Any 
developments that enable streamlining of the acquisition of representative data 
would clearly be most helpful but maintaining relevance to the patient and 
acceptability to regulators as a viable disease outcome measure remains the most 
crucial element still to be reconciled. 
 
Future directions for the work described in this thesis include further refinement of 
algorithms to detect MSCs within the bloodstream.  Ultimately this is likely to 
depend upon technological progress as well as the design of an appropriate 
algorithm before the goal is achieved.  Further evaluation of the inflammatory 
profile of the cell release in acute relapse and their correlation with the speed and 
degree of recovery may prove instructive in further identifying advantageous cell 
populations and refining therapeutic use.  Lastly, utilisation of larger datasets 
(including those that are acquired from the planned 100 patients entering the 
ongoing phase II study of autologous bone marrow transfer in relapsing-progressive 
MS in Bristol) to strengthen a number of primary findings in smaller pilot studies 
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